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Abstract
Alkaloids containing the nitrogen atom in the bridgehead position of two rings,
such as indolizidine, pyrrolizidine, and quinolizidine alkaloids, have a wide and varied
distribution in nature. Some of these alkaloids demonstrate a broad range of
pharmacological activities and have generated substantial synthetic interest. This thesis
covers the total synthesis of novel tylophorine analogs called DCB 3503, DCB 3506,
DCB 3507, DCB 3508, DCB 3509, and a derivative with a biotinylated chain attached to
DCB 3506 for use as a biological probe. This thesis discusses the biological activity of
these compounds as well.
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Chapter One: Synthesis of DCB 3503
1.1

Statement of Problem
The objective was to develop a scale-up synthesis of DCB 3503. The National

Cancer Institute showed in its anticancer screen that DCB 3503 (a synthetic compound,
Figure 1) had a potent growth inhibitory effect (GI50 ~ 10-8 M). To evaluate its antitumor
potential, synthesis and large scale preparation was required.

Figure 1: Structure of R1 = OH, R2 = H, R3,R4 = OMe DCB-3503
R1 = H, R2 = H, R3,R4 = OMe Tylophorine
R1,R4 = H, R2,R3 = OMe, Tylophora crebriflora
This highly potent anticancer compound needed to be synthesized in scale-up
conditions in order to do more biological analysis. This compound, DCB 3503, requires
at least 10 steps that involve reactions such as Perkin condensation 1, cyclization
through oxidative couplings,18 diastereoselective reduction2, intramolecular Friedel–
Crafts cyclizations1, hydrolysis, peptide bonds, alkylations1, and amino acid couplings.
These reactions required specific temperatures and molecular equivalent.
In the past, the synthesis of DCB 3503 took longer time to be synthesized and
the final compound yield was approximately 40–50 mg, therefore, the synthetic route
had to be improved.
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1.2 Introduction
Tylophorine and its analogs are phenanthroindolizidine alkaloids.3,4 These
natural compounds have been isolated primarily from the genera Cynanchum,
Pergularia, and Tylophora in the Asclepiadaceae family, but they have also been
reported from Hypoestes verticillaris (Acanthaceae), Cryptocarya phyllostemmon
(Lauraceae), as well as Ficus hispida and Ficus septica (Moraceae).
DCB 3503 is an analog of tylophorine and has an added secondary alcohol
moiety. Tylophorine is a pharmacologically active5 phenanthrolizidine alkaloid. It is the
major constituent of the plant Tylophorica indica (Asclepiadaceae). Its common names
are anthrapachaka (Sanskrit), country ipecac, and Indian ipecac, and it is a perennial
plant native to southern and eastern India.
Tylophorine has medicinal properties. It has been proved to have antitumor
activity,6 such as in breast cancer.2,7-9 It is an effective drug for bronchial asthma. This
plant is used to treat respiratory diseases. It is useful as a bronchodilator, an emetic,
and an expectorant. A similar compound from Tylophora crebriflora shows high activity
against leukemia L1210 in mice.7
Tylophorine has anti-inflamatory properties.10 The molecular mechanism for the
anti-inflamatory of phenanthroindolizidine alkaloids has been examined as an in vitro
system.11 Tylophorine exhibited a potent suppression of nitric oxide production and did
not show a significant cytotoxicity to the lipopolysaccharide interferons (LPS)/IFN-γ
stimulated RAW264.7 cells. The RAW264.7 cell line is used in an assay of IFN-γ that
measures the concentration of nitric oxide (determined by nitrite accumulation in the
culture medium) generated by RAW264.7 cell line.11
Tylophorine and its analogs such as DCB 3503 are commonly called tylophora
alkaloids. These analogs have been targets of synthesis and modification for their
significant cytotoxic activities.4 Tylophora alkaloids can be naturally extracted from its
natural source only in small quantities; therefore, DCB 3503 needed to be synthesized,
along with its prospective analogs, to find their molecular mechanism of action with
cancer cells.12,13

17

The Baker group has focused its efforts on the synthesis of DCB 3503 and
analogues for evaluation as anti-cancer,3 anti-arthritic,11 and anti-lupus drugs.14 Work by
Dr. S. Zhong, C. Kaczmarek15 and others have laid the foundation for this dissertation.
Biological collaborators include Prof. Yung-Chi Cheng and his group at Yale University
School of Medicine.

18

1.3 Results and discussion: DCB 3503 scale-up

Scheme 1: The synthetic route to DCB 3503.

Scheme 1, cont’d.
19
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1.3.1 Synthesis of (E)-2,3-bis(3,4-dimethoxyphenyl)acrylic acid (3)
The

synthesis

of

3

was

carried

out

by

condensation

of

3,4-

dimethoxybenzaldehyde and (3,4-dimethoxyphenyl)acetic acid in refluxing TEA and
Ac2O in excellent yield. This condensation, also known as Perkin condensation, yielded
a mixture of both (E) and (Z) isomers in a ratio of (10:1),16 but isomer (E) was obtained
exclusively by recrystallization.18 It has been noted that even without recrystallization,
isomer (E) and (Z) can be used for the subsequent intramolecular oxidative coupling in
order to obtain 5.17
It has been reported that for product

3 the (E) isomer displayed a characteristic

singlet resonance at 7.8 ppm for the vinylic β proton; the (Z) isomer for

3

displayed at

approximately 7.1 ppm. This characteristic singlet for the (E) isomer has been found at
7.8 ppm in the 1H NMR spectrum for product

3. It is important to indicate that a singlet

at 7.1 ppm was not found after recrystallization (see Figure 2).

Figure 2: Compound 3 (E) and (Z) isomer.

This condensation was improved in the following steps:
21

1. In a 15 g scale, addition of 3,4-dimethoxybenzaldehyde and Ac2O were added
until a solution was obtained. Then the TEA was added. At that moment, (3,4dimethoxyphenyl)acetic acid was added, and the mixture was slowly heated until
it reached 100 °C (~1 h).
2. Slowly H2O and a solution of K2CO3/H2O was added dropwise to the mixture (4–5
h).
3. The reaction was slowly quenched with 2 N HCl (2–3 h).
If these steps were followed, the product would always precipitate as yellow
powder in high yield. If these steps were not followed or the solutions were added
faster, the formation of a sticky oily product would occur, which stopped the stirring bar,
and addition of 2 N HCl could not quench the reaction.

22

Scheme 2: Proposed mechanism for the formation of (E)-2,3-bis(3,4-

dimethoxyphenyl)acrylic acid (3).
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1.3.2 Synthesis of (E)-methyl 2,3-bis(3,4-dimethoxyphenyl)acrylate (4)
The esterification of 3 was achieved by addition of methanol under strongly acidic
conditions. This reaction was improved to obtain high yields in the following steps:
1. The starting material was dissolved in methanol and left stirring untilall
components dissolved.
2. The solution was heated slowly until 60 °C was reached.
On the next day, the solution was left stirring until room temperature was
reached. Then, solvent was removed by vacuum evaporation at not higher than 30 °C
or the solution would turn into a purple oil. Under these conditions, the ester product 4
precipitated into a yellow powder in high yield and was washed quickly with cold
methanol.
Product

4 (E) isomer displayed a characteristic singlet resonance at 7.8 ppm for

the vinylic β proton. According to the literature, the (Z) isomer of

4 would be

displayed at approximately. 7.1 ppm.18 This characteristic singlet for the (E) isomer has
been found at 7.8 ppm in the 1H NMR spectrum for

4.

It is important to indicate that

singlet around 7.1 ppm was not found in the product (see Figure 3).

Figure 3: Structure of compound 4 (E) and (Z) isomer.
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1.3.3 Synthesis of methyl 2,3,6,7-tetramethoxyphenanthrene-9carboxylate (5):
Product 5 was obtained by two methods:
1.3.3.1 Method 1: VOF3

Scheme 3: Synthetic conditions to obtain 5.
Vanadium trifluoride oxide (VOF3) with trifluoroacetic acid (TFAA) was useful for
the cyclization of phenanthrene rings that contained methoxy groups as substituents. 2 It
has been demonstrated by Halton and co-workers18 that from a survey of derivatives
that oxygen functionality (-OMe groups) was necessary at the R4, R5 positions and/or
the R1, R2 positions of (B) of the aromatic rings for cyclization to occur, as illustrated in
Table 1.

Scheme 4: VOF3 reaction of compound 4 with R substituents
Table 1: Partial table made by Halton and co-workers18
R

1

R

2

R

3

R

4

R

5

R

6

VOF3/TFA % yield
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.

VOF3/BF3 Et2O % yield

a

OMe

OMe

H

OMe

OMe

H

74

95%

b

OMe

OMe

H

H

H

H

44

65

c

H

H

OMe

OMe

H

H

61

82

d

H

H

H

OMe

OMe

H

0

5 to 95

n

H

H

H

H

H

H

0

0

Halton and co-workers18 suggested the formation of a radical cation as a possible
mechanism using VOF3/TFA. Vanadium trifluoride oxide is believed to affect the
electron transfer and form radical cations with methoxy groups at the ortho position. It
was experimentally demonstrated in Halton and co-workers18 and Jin and co-workers17
that the two groups should be in the ortho position or the reactions failed. Vanadium
trifluoride oxide acts as an oxidizing agent. This substance can gain electrons in a redox
chemical reaction and becomes reduced in the process.
This mechanism is believed to involve electron transfer and form radical cations
on electron-rich substrates. Therefore, the aryl–aryl bond formation could occur by the
coupling of a pair of radical cations in the presence of -OMe at the R1, R2, R4, and R5
positions, followed by a radical attack on a un-ionized aryl group. This hypothesis is
also supported by Jin and co-workers.17 The cyclizations of phenanthere rings with OMe substituents at different position than R1, R2, R4, and R5 resulted in very low yield
as reported by Halton and co-workers.18 This demonstrates the lower yield for product

15 (only 2 –OMe groups in R4 and R5, chapter 2) compared to 5 (4
–OMe in R1, R2, R4, and R5 positions), because it shows that two methoxy groups or
oxygen functionalities are necessary in at least one of the aryl groups. These
mechanisms are a possible explanation for products

5

and

15

using VOF3. This

coupling occurred between these two aryl to give 5 which was evident for the newly
formed of four 1H NMR single peaks in the phenanthrene
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ring of compound 5.

Scheme 5: Proposed general mechanism for the formation of ring coupling.

27

1.3.3.2 Method 2: Anhydrous FeCl3
Anhydrous iron(III) chloride has been used to synthesize the phenanthrene ring
substituted with polymethoxy groups. This product is achieved via intramolecular
oxidative coupling of E and Z 5 isomers using anhydrous FeCl3 in EtOAc. Vanadium
trifluoride oxide (VOF3) can be used to form the phenanthrene ring as explained above;
however, this reaction was improved to use in the scale-up process. Vanadium
trifluoride oxide reagent has been limited due to toxicity, rigorous conditions, and price
(Table 2). Therefore, the use of anhydrous FeCl3 was ideal for scale-up process.
The conditions for the intramolecular oxidative coupling were simple. First, the
starting material was dissolved in DCM below -10 °C. It was noticed that at room
temperature the reaction was not completed, and a large amount of starting material
(60%) was detected by TLC. Secondly, a fresh solution containing FeCl 3 in EtOAc was
added dropwise. The reaction was completed as soon as the addition of FeCl 3/EtOAc
was finished. The product was monitored by TLC that gave a characteristic bright blue
color on anysaldehyde–H2SO4 spray.19 It was also noticed that for scales higher than
four grams the reaction was completed within 10 minutes.
Table 2: VOF3 and FeCl3 reaction time, toxicity, and price.
Reagent

Reaction time (1g scale)

Toxicity

Price (Fisher)

VOF3

4h

Corrosive

$25 (5 g)

FeCl3

10 min

Low toxicity

$22 (500 g)

Anhydrous iron(III) chloride was added in large excess. Even though FeCl3 was
completely dissolved in EtOAc, a large excess was needed to form the phenanthrene
ring. Lowering the mol equivalents of FeCl3 has been attempted, but the presence of
starting material was found. It is important to indicate that the FeCl3 must be anhydrous.
The use of FeCl3·6H2O resulted in low yields, apparently due to the presence of water.
The use of FeCl3·6H2O on silica gel was also investigated, but the reaction gave a lower
yield of product.
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Scheme 6: Proposed mechanism for the conversion of 4 (E) and (Z) isomers to 5.
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1.3.4 Synthesis of (2,3,6,7-tetramethoxyphenylphenanthren-9yl)methanol (6):
The reduction of 5 required one molecular equivalent of LiAlH4 to reduce the
ester group to a primary alcohol. This simple reduction gave high yield and was
quenched in by either of two methods:
1. EtOAc and 2 N HCl.
2. EtOAc and Na2SO4∙10H2O overnight
The second method provided perfect conditions to obtain high yield, because
Na2SO4∙10H2O is one of the ideal quenching reagents for sensitive compounds, and the
granular form of LiOH that resulted facilitated filtration and isolation of product.
The reduction of the ester formed homotopic methylene hydrogens. The 1H NMR
spectroscopy proved the complete reduction of the ester group to obtain the CH2
hydrogens at 5.14 ppm, it was also noticed that the ester –Me peak at 4.01 ppm from
compound 5 was not present.
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1.3.5 Synthesis of (S)-methyl 5-oxo-1-((2,3,6,7)tetramethoxyphenanthren-9-yl)methyl)pyrrolidine-2-carboxylate (7):
This reaction required three steps:
1. Halogenation: bromination of the alcohol was accomplished with PBr 3 in chloroform at
-10 °C. The reaction was carried it out in freshly distilled chloroform at cold
temperatures, which was important in order to increase the final yield. Previously,
chloroform was used directly from the bottle, and it gave a thick liquid as product, which
gave unsatisfactory 1H and

13

C NMR spectra and a low yield of the brominated product.

Under these circumstances the crude product was used in the next step continued
without any NMR characterization. However, after reading several papers with similar
reactions, it was decided to distill the chloroform in order to remove any ethanol present
(stabilizer) in the bottle. According to Fisher Scientific, chloroform only contains 0.75%
of ethanol, but using this freshly distilled chloroform the brominated product gave a high
yield and solid product that was easily characterized by NMR spectroscopy. Another
important point to increase the yield was during quenching the reaction with ice. It was
significantly important to let the ice melt completely and let the aqueous solution mix for
at least 30 minutes before any organic extraction was attempted to significantly improve
the quality of brominated product. If the organic extraction was separated in the
presence of ice, the brominated compound did not turn solid even when distilled
chloroform was used (see Scheme 7).

Scheme 7: Procedure to transform OH to Br.
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2. Coupling of L-glutamic ester HCl: The coupling of the brominated compound with Lglutamic ester HCl was also significantly improved. In the past, this coupling was
achieved by mixing the halogenated compound, the amino acid, and K 2CO3 in DMF at
the same time, and the reaction was run overnight at room temperature. The reaction
was improved by mixing the brominated intermediate with the L-glutamic ester HCl
completely and then adding K2CO3; the reaction was run from 65–70 °C overnight. This
range of temperature was important, because it was found that any higher or lower heat
will considerably lower the yield of the product. The ESI+ mass spectrometry for this
intermediate was obtained and indicated complete coupling without any brominated
starting material.

Scheme 8: Alkylation of amino acid side chain.

3. Closing of the amino acid side chain: This final step was achieved by mixing the
amino adduct in MeOH and AcOH. This reaction was improved as well. In the past, this
reaction was accomplished by mixing MeOH and AcOH overnight at room temperature.
The final product yield was improved by adding a 1:1 molar ratio of MeOH:AcOH and
increasing the temperature up to 35 °C overnight. The temperature in this step was
crucial. From experience, any temperature greater than 40 °C would decrease the yield.
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Scheme 9: Closing amino acid side chain.

1.3.5.1 Important NMR observation for diastereotopic hydrogens on
C11 for product 7.
Geminal coupling 2J (H,H), bond angle, and effect of neighboring  electrons for
diasterotopic hydrogens on C11.
Bond angle
Geminal coupling or 2J coupling is dependent upon the bond angle between the
nuclei. Generally, the smaller the angle the bigger the coupling constant. The bond
angle for the geminal hydrogens on C11 was 109.5°. This bond angle was calculated by
drawing the structure in Tripos: Sybyl 8.0 molecular modeling program (molecular
dynamics and MM4 minimization were used), as shown in Figure 4. She Figure 4
indicates the dependence of the coupling constant on bond angle.

Figure 4: Coupling constant vs bond angle.
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Dependence of the magnitude of the geminal coupling constant on C11, J =
14.60 Hz, and the HCH angle = 109.5° correlated with the expected values according to
the graph above.
Geminal coupling 2J (H,H)
The diastereotopic hydrogens on C11 showed two distinct chemical shifts at 4.4 and 5.5
ppm, 2J (H,H) = 14.60 Hz as shown in Figure 5

and 6. It was noted that these

hygrogens were homotopic in starting material 6 before coupling to obtain product 7.
The effect of neighboring  electrons.
There are several major factors that affected the geminal coupling constant:20
1. The hybridization of the atoms involved in the coupling.
2. Bond angles and torsional angles.
3. Bond length.
4. The presence of neighboring -bonds.
5. Effects of neighboring electron lone-pairs.
6. Substituent effects.
The diastereotopic hydrogens on C11 have different chemical shift primarily due
to the neighboring -bonds and electron lone-pairs from the amide group. This effect
was clearly present when the amide was formed in the intermediates, but the difference
in chemical shifts was noticeably smaller when the amide was reduced to a tertiary
amine by LiAlH4 to obtain compound 11. The new chemical shifts for the diasteretopic
hydrogens on C11 were 2.8 and 3.1 ppm for compound 11.
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Figure 5: J Coupling of compound 7 at 4.42 ppm.
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Figure 7: Molecular modeling structure of compound 7.

37

1.3.6 Synthesis of (S)-5-oxo-1-(2,3,6,7-tetramethoxyphenanthren-9yl)pyrrolidine-2-carboxylic acid (8):
The hydrolysis of the ester 7 was accomplished under basic conditions of 2 N
KOH followed by quenching by 2 N HCl. In the past, this reaction was quenched by
H3PO4 until pH 3 at -10 °C. The product precipitated at low temperatures overnight, so it
was left inside the freezer to maximize the yield of product. This saponification method
did give a good yield, and it would often form a great excess of white salts that mixed
with the product 8 (white crystals). Thus, a mixture of product 8 and salts was
unavoidable. In order to remove these salts, we had to add quickly cold water to
dissolve the salts, but the water would dissolve the carboxylic acid product 8 as well.
The addition of H3PO4 was stopped when pH 3 was reached, but lowering the pH
to 1 did not help to avoid the formation of salts. It is important to indicate that any small
presence of this salt for the next step would lower the cyclization reaction yield.
Therefore, it was decided to add 2 N HCl until pH 1 was reached and extract the organic
product with CHCl3, DCM, and Et2O. In this way, no salts were formed and nothing
precipitated. The carboxylic acid was extracted with CHCl3, DCM, and Et2O to obtain a
yield of 95%. Product 8 was polar and soluble in water; thus it is essential to point out
the necessity to extract the product with CHCl3 at least five times. The completed
extraction was indicated by TLC (one spot seen at Rf = 0, since the carboxylic acid does
not migrate on silica gel TLC plates). For details, see Experimental section
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1.3.7 Synthesis of (S)-2,3,6,7-tetramethoxy-13,13a
dihydrodibenzo[f,h]pyrrolo[1,2-b]isoquinoline-11,14(9H,12H)-dione (9):
Product 9 was obtained using two methods:
1.3.7.1 Method 1: TFAA and BF3·Et2O
The carboxylic acid

8 was converted to its mixed trifluoroacetic anhydride by the

addition of trifluoroacetic anhydride in 1,2-dichloroethane or dichloromethane at room
temperature. The compound was treated with the Lewis acid BF3·Et2O and queched
with K2CO3, yielding the phenanthrene cyclized amido ketone 9.21 This improved
method was perfect for scale-up conditions, contrary to Method 2 that used SnCl4.
These ketones exhibited a markedly characteristic yellow spot on TLC under
ultraviolet absorption using anysaldehyde–H2SO4.19
This Friedel–Crafts cyclization had a higher yield when the solvent 1,2dichloroethane was used instead of dichloromethane. The choice of solvent was
important to obtain higher yield and purity of the ketone. The final yield, after running a
silica gel column, using 1,2-dichloroethane was around 70%; on the other hand, using
dichloromethane the yield was 20–50%.
A possible explanation for this lower yield could be the formation of
rearrangements or by-products as expected by Bourry21,22 and Akué-Gédu.1 These byproducts were not detected by mass spectrometry for compound 9. Therefore, the
reaction using BF3·Et2O as a Lewis acid apparently did not give a higher yield than 70%.
The main concern was the formation of an alcohol chain by using
dichloromethane as solvent at reflux. This by-product 9.1 could be formed that
contained a CH2OH group in the α-position to the newly formed ketone function under
reflux conditions.21 Therefore, in order to avoid this by-product, the Friedel–Crafts
reaction using BF3·Et2O as Lewis acid must be run at room temperature. From
experience, the expected ketone 9 was not formed when the reaction was heated to
reflux overnight in an attempt to increase the yield. The formation of this by-product was
explained and presented in Scheme 10.21
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Scheme 10: Cyclization of compound 8 at reflux.

Scheme 11: Proposed mechanism for formation of 9.1.
A boron enolate 9A (Scheme 11) could be formed from the reaction of excess
BF3·Et2O with the ketone 9 in the presence of trifluoroacetic acid (by-product after
cyclization). Then, the remaining dichloromethane can be reacted with the enolate to
give the chloromethyl ketone 9B. Therefore, dichloromethane was evaporated before
40

addition of K2CO3/H2O to avoid this by-product. The final step was the hydrolysis of the
chloromethyl ketone using K2CO3/H2O to form 9.1, see Scheme 11.

Scheme 12: Mechanism for the formation of compound (9) at room temperature.

The characterization of product 9 was fully supported by 1D/2D NMR
spectroscopy and MS. After cyclization, the H1 on C1 of each phenanthrene underwent
a noticeable downfield shift due to the deshielding of the newly formed ketone. This
effect was reversed after reduction with K-selectride for the formation of the secondary
alcohol (see Table 3). This downfield shift was also reported in the publication by
Buckley and Rapoport.2
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Table 3: Comparison of 1H and 13C NMR shifts for compound 8, 9, and 10

Compound 8
1

H
H1

ppm
7.16

13

ppm
104.26

13

ppm
108.14

13

ppm
104.46

C
C1

Compound 9
1

H
H1

ppm
7.72

C
C1

Compound 10
1

H
H1

ppm
7.59

C
C1

1.3.7.2 Method 2: Oxalyl chloride and SnCl4
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The desired completion skeleton of DCB 3503 was accomplished under Friedel–
Crafts conditions using (COCl)2 to obtain an acid chloride to activate the carboxylic acid
with SnCl4 as the Lewis acid. (see Scheme 16). This intramolecular Friedel–Crafts
reaction consistenly gave a yield (60–70%) of product 9.
Tin(IV)chloride is hygroscopic, toxic, and expensive; therefore, this reagent had
to be replaced by an easier-to-handle, less toxic, and inexpensive Lewis acid in order to
be applied for a scale-up process (see Table 4).
In order to quench the excess of SnCl4, addition of 20 mL of water in 1 mL
increments was useful before addition of 2 N HCl. Water quenched the SnCl 4 slowly
and gave a higher yield of a cleaner product. This mixture of water and 2 N HCl could
not stay for more than 1 hour; otherwise, the compound 9 would decompose.
Table 4: SnCl4 and BF3·Et2O reaction time, toxicity, and price

Reagent

Reaction time (1 gram scale) Yield %

Toxicity

SnCl4

6h

70

BF3·Et2O 5 h

70

toxic
Low
toxicity
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Price
(Fisher)
$37 (100 mL)
$66 (1 kg)

Scheme 13: Proposed mechanism for the SnCl4-mediated synthesis of 9.
Scheme 13, cont’d

1.3.8 Synthesis of (13aS, 14S)-2,3,6,7-tetramethoxy-9,11,12,13,13a,14hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-14-ol (11)
The final product was achieved by reduction of the amide group using 1
molecular equivalent of LiAlH4. Unfortunately, this reaction did not give as high a yield
as the previous reactions. This can be attributed to the sensitivity of the final compound
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to harsh conditions such as the strong reducing agent. The final yield varied from 60–
80% depending on the quenching method. Two quenching methods were applied:
1. Ethyl acetate and 2 N HCl for 30 minutes.
2. Ethyl acetate and Na2SO4∙10H2O for 2 h or overnight.
The best conditions were adding ethyl acetate at -10 °C and then stirring with
Na2SO4∙10H2O for 3 h. Any other quenching method proved to lower the yield of
product.
In order to purify the crude product, column chromatography was used. The
solvent system was 2:1:0.2 CHCl3:EtOAc:MeOH. Even though 11 was a highly polar
compound, there was an unwanted side-product with m/z = 411.19 and [M+1]+ = 412.20
that was detected using the DART mass spectrometer in positive-ion mode and by
HPLC. The detection and separation of this side-product was difficult due to its similar
polarity with that of 11, no coloration with anysaldehyde–H2SO4, and a close molecular
weight to that of 11 (DCB 3503 = 409.19, [M+1]+ = 410.19). The only solvent method
found to completely separate this side-product was 2:1:0.2 CHCl3:EtOAc:MeOH .
An alternative synthetic route and biological analysis of this side-product is
described in Chapter 3.
1.3.8.1 Molecular modeling and dihedral angle between H14 and H13a:
Tripos: Sybyl 8.0 with MM4 was used to calculate the dihedral angle between
H14 and H13a for product 11. This program was highly useful to determine the lowest
energy conformation and predict the dihedral angle.
The direct drawing using molecular modeling SYBYL 8.0:Tripos (minimization
with MM4 and molecular dynamics). Figure 8.
The predictions for dihedral angle and final energy can be seen in Table 5.

Table 5: DCB 3503 dihedral angle molecular modeling results
Structure
Dihedral angle
Final
steric
(kcal/mol)
DCB 3503 from drawing

51.1

12.5425
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energy

Figure 8: Compound 11 direct drawing and minimization molecular modeling.
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1.3.9 Attempted cyclization of 28 with (S)-2(methoxycarbonyl)pyrrolidinium chloride to obtain 29.
A tentative pathway for the cyclization of

28 (Scheme 15)

was

unsuccessful. Similar Lewis acids, such as AlCl323, BF3·Et2O, SnCl4, and Sm(OTf)3,
were tried to obtain the intramolecular cyclization, but these reagents were not suitable
for the reaction. The coupling of the brominated intermediate 6.1 with the closed amino
acid (S)-2-(methoxycarbonyl)pyrrolidinium chloride was highly successful giving
excellent yield, see Scheme 18. The hydrolysis of

24 was a success giving 28 in high

yields using 2 N KOH or NaOH.24 The next step was a failure, a different Lewis acids,
molecular equivalents, variable temperatures, extended reaction times, different
chlorination of carboxylic acids, and quenching methods failed to yield the ketone

29.

Due to this failure of Friedel–Crafts cyclization, further efforts in this area were
abandoned. Later on, it was found that Buckley and Rapoport 2 also tried to these
reagents with the free amido compound 28, and the results were unsuccessful as well.
Chauncy attempted the cyclization of this free amide to also obtain negative
results.7 Cycloalkylation of using AlCl3, BF3∙Et2O, Sm(OTf)325, SnCl4 (at reflux)26 proved
unsuccessful as well. According to his paper,7 he was successful to obtain the
cyclization by using phosphoric acid at 90 °C with yields of 20–35%. These conditions
were tried on 28, but it did not dissolve in phosphoric acid, even at high temperature
around 200 °C. The procedure was abandoned. This reaction would have been highly
useful because it would had eliminated two steps, and the necessity to reduce the
amide, which gives a lower yield due to the sensitivity of the final compound 11 under
strong reducing agents.
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A = CO2Cl2
B = SnCl4

SOCl2
AlCl3

CO2Cl2
Sm(OTf)3

TFAA
BF3·Et2O

Scheme 14: Attempted cyclization of 28.
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SOCl2
SnCl4

CO2Cl2
AlCl3

Chapter Two: Synthesis of DCB 3507
2.1

Statement of Problem

The objective was to effect the synthesis of an analog of DCB 3503 that lacked
the MeO groups in the 6, 7 –position of the phenanthrene ring (see Figure 9).
The anticancer activities are to be examined to add to structure–activity
relationship development among these compounds.

Figure 9: Structure of DCB 3507.
DCB 3507: R1, R2 = H, R3 = OH
Antofine: R1 = OMe, R2,R3 = H, (S) 13aH
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2.2 Introduction
The synthesis of DCB 3507 started in an undergraduate summer program
sponsored by UT Science Alliance for two consecutive summers. This project was
under the direct supervision of Dr. David C. Baker and Mr. Conrad Kaczmarek.
The main objective to synthesize DCB 3507 was to find whether there was any
difference in biological activity compared to DCB 3503, since it was a similar analog. In
this way, it could give valuable information about structure–activity relationships and
prove if four methoxy groups were absolutely necessary for biological activity against
cancer cells.
A number of examples of Tylophorine analogues are known that lack 6, 7
methoxy groups. One example is the antofine analogues. Their antitumor activity with
different susbtituents on the phenanthrene ring has a variety of citotoxic activity against
various cancer cells with lower potency than DCB 3503. However, no 6,7–desmethoxy
derivative of DCB 3503 is known.
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2.3 Results and discussion: Total synthesis of DCB 3507

Scheme 15: The synthetic route to DCB 3507.
Scheme 16, cont’d
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2.3.1 Synthesis of (E)-3-(3,4-dimethoxyphenyl)-2-phenylacrylic acid
(13)
2.3.1.1 Condensation reaction to give C.
The synthesis of C was first attempted in order to obtain a tylophorine analog
with two methoxy groups in the phenanthrene ring moiety, as seen on Scheme 16.

Scheme 16: Condensation reaction to obtain C
This condensation reaction of C started with commercially available reagents.
The synthesis required 3,4-dimethoxyphenylacetic acid (A, 30 g), benzaldehyde (B, 30
g), TEA (46 mL), and Ac2O (80 mL). This reaction was left running overnight at 100 °C.
The detailed experimental observations can be found in the Appendix section.
2.3.1.2 Condensation reaction to give 13.

Scheme 17: Condensation reaction to obtain 13.
The starting material was changed to synthesize DCB 3507 using two methoxy
groups in positions 2 and 3 of the phenanthrene ring, as seen in Scheme 17. The
starting commercial materials were 3,4-dimethoxybenzaldehyde (veratraldehyde 1), and
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phenylacetic acid 12. The detailed experimental observations can be found in the
Appendix section.
The product 13 was characterized and verified by using NMR and mass
spectrometry. The theoretical exact m/z was 284.105, and the experimental m/z was
found 285.111 using AccuTOF–DART in positive-ion mode. The key hydrogen
resonance that verified the condensation reaction and stereochemistry product 13 was
the characteristic singlet resonance ~7.8 ppm in the vinylic β hydrogen (H β) for the (E)
isomer. The undesired (Z) isomer would show Hβ ~7.1 ppm although the (Z) isomer
was present in a ratio of 10:1, the (Z) isomer was not detected after recrystallization
(See Figure 12).

Figure 10: Compound 13 (E) and (Z) isomers.
The Hβ in 13, which was originally the aldehydic H in the starting material 1, is
more shielded in the (E) alkene (See mechanism in Scheme 19)
It is known that hydrogen from aldehyde groups is shifted around 9.5–10 ppm,
and alkene protons range from 4–5 ppm (without substituents), but this newly formed
alkene Hβ was found at 7.891 ppm. This shift was expected due a large deshielding
effect from to the benzene ring. In Figure 11 the benzene and the alkene are coplanar,
so the Hβ is further deshielded because of the additional deshielding effect from the
double bond of the ketone.
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Figure 11: Ring current effect in arenes and compound 13 in plane view.
The Hβ indicated the stereochemistry for the desired (E) isomer over the
undesired (Z) isomer. The desired (E) isomer showed the predicted Hβ singlet at 7.891
ppm, and the undesired singlet at 7.1 ppm was not found in the proton spectrum 18 see
Figure 12.
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Scheme 18: Proposed mechanism for the formation of (E)-3-(3,4-

dimethoxyphenyl)-2-phenylacrylic acid (13)
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2.3.2 Synthesis of methyl 2,3-dimethoxyphenanthrene-9-carboxylate
(15)
2.3.2.1 Method 1: VOF3

Scheme 19: VOF3 reaction to obtain 15.
Vanadium(V) oxytrifluoride was used to form the phenanthrene system (Scheme
19).2 This reaction was applied according to H. Pearson’s27 procedure. These reaction
conditions were later successfully applied to DCB 3503, and a high yield of product was
obtained. The newly formed phenanthrene ring showed a bright blue spot on TLC under
anysaldehyde–H2SO4 stain.
This oxidative coupling reaction required at least 4.4 equivalents of VOF 3 to close
the ring.5 A low yield was obtained as an attempt to lower the amount of VOF 3 needed.
A mixture of starting material and product was seen on TLC and mass spectrometry.
The separation of the product and starting material was difficult, because these two
products had similar polarity; therefore, they could not be separated completely.
The use of VOF3 gave a high yield, but it had to be replaced by another reagent
due to its high cost and limited amounts that were commercially available; therefore,
VOF3 was not suitable to scale-up reactions.
2.3.2.2 Method 2: FeCl3/SiO2
It has been proved that silica-bound ferric chloride (FeCl3/SiO2) can serve as an
oxidant for aromatic coupling (Scheme 20).28 The results indicated that solid-supported
FeCl3 could act as an electron-transfer oxidant29 and it was environmentally better than
VOF3.16 This reaction provides an effective and less expensive (compared to VOF 3)
reagent for coupling of aromatic rings.
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Scheme 20: FeCl3/SiO2 to obtain 15.
The use of silica gel/FeCl3 as a solid-supported oxidant was the key to obtaining

15.

a higher yield in the intramolecular coupling reaction of

Anhydrous FeCl3 and

FeCl3–SiO2 serve as Lewis acids for oxidative coupling reactions. The use of FeCl3 in
EtOAc showed a very low yield (<15%) due to the lack of methoxy groups as explained
for DCB 3503 in intermediate 5 by Halton and co-workers.{Brian Halton, 1984 #8} As an
alternative reagent, VOF3 can be used to form the phenanthrene ring, but this reagent is
expensive and toxic. Therefore, it could not be used for scale-up conditions (see Table
6).

Table 6: VOF3 and FeCl3/SiO2 reaction time, toxicity, and price
Reagent

Reaction time (1 gram scale)

Toxicity

Price (Fisher)

VOF3

4 hours

FeCl3/SiO2

48 hours

corrosive $25 (5 g)
Low
toxicity
$22 (500 g)

The formation of 15 was verified and characterized by mass spectrometry and
NMR spectroscopy. The exact molecular weight of 15 is 296.105, and ion was found at
[M+1]+ = 297.106 using the AccuTOF DART in the positive-ion mode. The
characterization by NMR spectroscopy was used (1H,

13

C, and 2D NMR such as

gHSQC and NOESY) to prove the structure.
The most important

1

H NMR spectroscopy characterization of 15 was the

formation of the phenanthrene system see Figure 13.
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Figure 13: Compound 15, phenanthrene ring in bold.
The phenanthrene ring is a benzene derivative that is categorized as an aromatic
compound; therefore, the chemical shifts spin–spin splitting, J coupling for 15 gave the
following expected results (see Table 7):
Table 7: Chemical shift, splitting, and J coupling for 15
Hydrogen
Chemical shift (ppm) Splitting

J coupling (Hz)

H1

7.98

Singlet

0

H4

8.44

Singlet

0

H5

8.99

Doublet

8.39

H6

7.62

Triplet

7.28

H7

7.64

Triplet

7.30

H8

7.25

Doublet

8.23

H10

8.55

Singlet

0

NMR spectroscopic analysis:
1. Chemical shifts: the seven aromatic protons showed the correct peaks in the
aromatic region (6–9 ppm) due to the formation of the phenanthrene system. The
chemical shift values for H1, H4, and H10 were expected to be less shielded due
to the proximity of the methoxy groups in C2 and C3, and the ester group in C9.
The rest of aromatic protons H6, H7, and H8 had to have similar shifts and be
more shielded due to a similar environment with only hydrogens as neighbors.
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2. Splitting: the splitting of H1, H4, and H10 had to be singlets, because they did not
have any hydrogens as neighbors for spin coupling. The H5 and H8 showed the
correct doublet as splitting for being only next to H6 and H7 respectively. The H6
and H7, showed the expected triplet for having two hydrogen neighbors in H5,
H7, and H6, H8 correspondingly.
3. J coupling: The J coupling for H1, H4, and H10 were zero because they were
singlets. The J coupling for H5, H6, H7, and H8 gave interesting results. It was
expected very similar J coupling values for H5, H6, H7, and H8, but two different
ortho coupling constants were found: 3J5,6 = 8.39 Hz and 3J6,7 = 7.28 Hz, also
3

J8,7 = 8.23 Hz, and 3J7,6 = 7.30 Hz, which can be seen in Figure 14 .

Figure 14: Ortho coupling constants for (15).
The main reason for this J coupling difference is due to the different C–C bond
lengths in the aromatic system.20 A similar example was found for naphthalene in
Friebolin20, which is shown in Figure 15.

Figure 15: Naphthalene J coupling according to Friebolin.20
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Scheme 21: Proposed mechanism for the synthesis of 15 using VOF3 or FeCl3.
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The mixture of SiO2 in FeCl3 was made fresh for the intramolecular coupling
reaction. A certain amount of SiO2, preferably 1 equivalent, was left drying overnight at
80 °C in the oven to avoid any moisture present in the silica gel. This dry SiO 2 was
poured into a mortar that contained 1 equivalent of FeCl3. These reagents were ground
and mixed using a mortar and pestle. This mixture was poured immediately into a
starting material solution of that in dichloromethane to be run for at least 48 hours at
room temperature.
The dryness of SiO2 was important for the experimental conditions. It was noticed
that regular SiO2, without being dried in the oven overnight, gave low yields, and
difficult-to-run columns were necessary to separate the product and starting material.
The formation of the phenanthrene ring must be done prior formation of the
alcohol by reduction. This reaction gave almost no product and a tacky solid if any
hydroxyl group, including phenols was present in the starting material. See Scheme 22.

Scheme 22: FeCl3 reaction in the presence of hydroxyl group.
The possible side-product and mechanism was presented by Krishna et al.30
There are possibilities that FeCl3 reacts as a Lewis acid and coordinates with the
oxygen of the alcohol, facilitating nucleophilic attack of another alcohol on the electrondeficient primary carbon, which is followed by deprotonation and regeneration of FeCl3.
As a result, the FeCl3 reagent gives an ether instead of the expected aromatic
phenanthrene ring (see Scheme 23).
The formation of the ether could be the answer for the formation of the tacky
product. This undesired product did not indicate the presence of any unreacted starting
material; therefore, it could not be recycled.
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Scheme 23: Proposed mechanism for FeCl3 reagent in the presence of OH group.
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2.3.3 Synthesis of (2,3-dimethoxyphenanthren-9-yl)methanol (16)
The reduction of 15 was accomplished by using one molecular equivalent of
LiAlH4 to reduce the ester carbonyl to methylene hydrogens (see Scheme 24).

Scheme 24: Reduction of compound 15.
These methylene hydrogens were homotopics and showed only one peak in the
1

H NMR spectrum. It was also noted that the ester peak at 4.05 ppm from compound 15

was not present after the reduction.
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2.3.4 Synthesis of (S)-methyl 1-((2,3-dimethoxyphenanthren-9yl)methyl)-5-oxopurrolidine-2-carboxylate (17)
2.3.4.1 AB Spin system
The synthesis of intermediate 17 required three steps from the alcohol 16. The
same steps and conditions were repeated from intermediate 7 to synthesize
intermediate 17.
Intermediate 17 was characterized by 1H,

13

C, gCOSY, gHSQC, and NOESY

NMR spectroscopy. Some features of the 1H NMR spectrum are worth mentioning. The
C11 protons in the tetracyclic base appeared as an AB spin system in NMR
spectroscopy (see Figure 16). It is important to indicate that this effect was not seen in
intermediate 7 due to the homotopic methylene protons.
In the 1H NMR spectrum it can be seen that the four signals for the methylene
protons on C11 in the region 5.5 to 4.4 ppm were not homotopic (equal intensities or
one signal), because they had different magnetic shieldings. As a consequence, they
gave separate signals. This feature is also known as “roof effect” or AB spin system.
The inner lines were stronger than the outer lines.
Analysis of the AB spin spectrum:
It started by numbering the resonances frequencies of the four lines of the AB
spectrum from left to right as f1, f2, f3, f4. As in the AX spectrum the coupling constants
JAB is equal to the frequency interval between lines 1 and 2 or between 3 and 4:
IJABI = If1 – f2I = If3 – f4I [Hz]
IJABI = I5.577 – 5.529I = I4.486 – 4.437I = 14.55 Hz
The chemical shifts are given by the centers of gravity of the line pairs 1, 2, 3,
and 4. The chemical shifts difference can be determined by the following equation:
∆v = √I(f1 – f4) – (f2 – f3)I
√ (5.577 – 4.437) – (5.529 – 4.486) = 0.314 ppm = 0.311 * 300 = 94.48 Hz
The roof effect is a typical indication of strongly coupled spin systems. In the
case ∆v is zero, only a singlet appears in the spectrum. It means the AB system is
essentially changed to an A2 spectrum.
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2.3.4.2 Geminal coupling 2J (H,H), bond angle, and effect of neighboring 
electrons for methylene protons on C11 of 17.
Geminal coupling 2J (H,H)
The diastereotopic hydrogens on C11 (4.5 and 5.6 ppm) also showed a
noticeable difference in chemical shifts, just like its analog intermediate 8. The geminal
coupling constant was found to be 2J (H,H) = 14.55 Hz.
Bond angle
The bond angle for the geminal hydrogens on C11 was also calculated drawing
the intermediate using molecular modeling: Tripos: SYBYL 8.0 (dynamics, MM4
minimization energy) as shown in Figure 17. The bond angle = 109.5°. It can be
observed that 2J(H,H) = 14.55 Hz correlated with the predicted bond angle 109.5° in
Figure 17.
The major effect for the difference in the diastereotopic hydrogens in C11 was
the presence of the amide group as explained for intermediate 8. This difference was
smaller (2.9 and 3.2 ppm) when the amide was reduced to the tertiary amine with LiAlH 4
to obtain 21 (DCB 3507).

Figure 17: Coupling constant vs bond angle.
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Figure 18: Structure of compound 17 from molecular modeling.
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2.3.5 Synthesis of (S)-2,3-dimethoxy-13,13adihydrodibenzo[f,h]pyrrolo[1,2-b]isoquinoline-11,14(9H, 12H)dione (19)
Compound 19 was obtained by two methods:
2.3.5.1 Method 1 TFAA and BF3·Et2O
The intermolecular Friedel–Crafts cyclization reaction of 18 using TFAA and
BF3·Et2O was accomplished under the same conditions as used for 9 to obtain the
ketone 19.21
2.3.5.2 Method 2 (COCl)2 and SnCl4
This cyclization was also obtained using (COCl)2 and SnCl4. Oxalyl chloride was
added to prepare the carboxylic acid chloride, and tin tetrachloride was used as a strong
Lewis acid to promote electrophilic addition to the aromatic system. This reaction
required heating at 30 °C prior addition of SnCl4, but it was noticed that a higher yield
was obtained when it was run at room temperature for at least four hours or overnight.
In order to quench the reaction, addition of 2 N HCl was needed. This weak acidic
solution must be added dropwise. It should be noted that water must be added before 2
N HCl decompose the SnCl4. The characteristic yellow spot was also observed on TLC
under ultraviolet light using anisaldehyde for both methods.
Intermediate 18 was characterized by 1H,

13

C, gCOSY, gHSQC, and NOESY

NMR spectroscopy. The C9 protons appeared as an AB spin system. The NMR
spectrum with the chemical shifts and the coupling constant are shown in Figure 19. It is
important to indicate that this effect was also seen in intermediate 8.
In the 1H NMR spectrum it can be seen that the four signals for C9 protons in the
region 5.9 to 4.8 ppm did not have equal intensities. This feature is also known as “roof
effect” or AB spin system. As in the AX spectrum the coupling constants JAB is equal to
the frequency interval between lines 1 and 2 or between 3 and 4:
IJABI = If1 – f2I = If3 – f4I [Hz]
IJABI = I5.873 – 5.812I = I4.806 – 4.745I = 18.3 Hz

70

Figure 19: AB spin system (roof effect) of compound 19.
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The aromatic H1 chemical shift of phenanthrene 18 undergoes a downfield shift
due to the deshielding of the newly formed ketone 19. This effect was reversed after
reduction of 19 with K-Selectride with the formation of the secondary alcohol 20 (see
Table 8).
Table 8: Comparison of 1H and 13C NMR shifts for compound 18, 19, and 20

Compound 18
1

H
H1

ppm
6.93

13

ppm
119

13

ppm
125.1

13

ppm
104.47

C
C1

Compound 19
1

H
H1

ppm
9.03

C
C1

Compound 20
1

H
H1

ppm
7.6

C
C1
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Product 19 was always produced in lower yield than 9. The percent yield ranged
from 50–60%. Several conditions were changed, such as temperature, molecular
equivalents of TFAA, mol equivalent of BF3·Et2O, reaction time, and quenching time to
improve the yield, but the cyclization could not be improved.
A possible explanation for this lower yield can be explained by Akué-Gédu and
co-workers.1 They postulated that the presence of deactivating functional groups in the
aromatic moiety decreased the rate of ketone formation. On the other hand, cyclization
of acids with electron-rich aromatic moieties gave better yields. Akué-Gédu et al gave
the following examples, Scheme 25.1

Scheme 25: Akué-Gédu’s reaction example
Thus, the presence of electron-rich methoxy groups in the phenanthrene ring
activated the aromatic moiety to form the Friedel–Crafts cyclization of 18. In the reaction
mechanism, shown in Scheme 26, it can be observed that after the cyclization produced
by the  aromatic bond on C9–C10, it formed a carbocation on C9. This positive charge
can be delocalized in the phenanthrene due to the aromatic  bonds. This delocalization
can be enhanced by the presence of electron-donating groups, in this case methoxy
groups (OMe), which donate their lone-pair of electrons localized on the oxygen. These
pair of electrons created a resonance to delocalize the positive charge. It is worth
mentioning, that the presence of only two methoxy groups vs. four methoxy groups
appears to have lowered the yield. The two methoxy groups 9 gave a lower yield than
the four methoxy groups 19; meanwhile, according to the literature, the total absence of
electron-donating groups (only hydrogens) or the presence of electron withdrawing
groups on the phenanthrene ring produced almost zero percent yield. Such behavior is
in line with electrophilic aromatic reactions in general and Friedel-Crafts reactions in
particular.
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Scheme 26: Reaction mechanism for the synthesis of 19.
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2.3.6 Synthesis of (13aS, 14S)-14-hydroxy-2,3-dimethoxy-12,13,13a,14tetrahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-11(9H)-one (20)
Stereocontrolled ketone reduction of the intermediate 19 on C14 to the
secondary alcohol 20 with (S) stereochemistry was achieved by either K-selectride or Lselectride in high yield. The decision to synthesize the secondary alcohol with the (14S)
stereochemistry was mandated given the higher biological activity of (14S) DCB 3503 in
contrast to (14R) DCB 3501 (see Scheme 27).

Scheme 27: DCB 3503, 3501, and undesired product
The two diastereotopic protons on C9 have noticeably different chemical shifts.
This difference is around 1 ppm (4.5 and 5.4 ppm). This chemical shift difference could
be due to the oxygen’s lone pairs of the amide group that deshielded the hydrogen on
the same face of the nitrogen, which is more downfield; meanwhile, the other hydrogen
is more upfield because it is more shielded as shown in Figure 20.
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Figure 20: C9 diasteromeric protons of compound 20.
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2.3.7 Synthesis of (13aS, 14S)-2,3-dimethoxy-9,11,12,13a,14hexahydrodibenzo[f,g]pyrrolo[1,2-b]isoquinolin-14-ol (21)
The reduction of the amide or lactam intermediate 20 to a tertiary amine 21 was
achieved by 1 equivalent of LiAlH4 with high yield. This reduction was quenched by
EtOAc and two options: 2 N HCl or Na2SO4∙10H2O. It was noted that using the second
reagent gave a little higher yield because the final product is more stable under neutral
conditions, instead of acidic or basic conditions. Unfortunately, this product was
unstable and tended to decompose when exposed to light, air, and solvent.
Final product 20 was characterized by 1H,

13

C, gCOSY, gHSQC, and NOESY

NMR spectroscopy. The C9 protons did not appear as an AB NMR spin system like the
previous intermediates. The C9 proton chemical shifts moved upfield due to the
reduction of the amide, from 4.5 to 5.4 ppm and from 2.9 to 3.2 ppm. It is clear that the
deshielding effect of the amide kept the C9 protons at downfield. This difference
became really shorter when the lactam was reduced with LiAlH4 to obtain the final
product 21 as shown in Figure 21. The effect of neighboring -electrons from the amide
group caused a negative contribution to the geminal coupling.
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2.3.8 Karplus equation and molecular modeling applied to DCB 3507
DCB 3507 has a secondary alcohol on C14 with a stereochemistry (S) due to a
previous stereoselective reduction using K-Selectride. In order to confirm this
configuration, some analysis was done to confirm this chiral carbon that included
dihedral angle,

3

J coupling constant, Karplus equation, and molecular modeling

(Tripos:SYBYL 8.0).
2.3.8.1 Dihedral angle analysis
DCB 3507 has a dihedral angle between hydrogens on H14 and H13a as shown
in Figure 22.

Figure 22: Dihedral angle case A and case B
The chirality is defined as 13aS by synthesis from the precursor amino acid 17.
There was no evidence of racemization during synthesis which would have produced a
diastereomeric mixture that would have been seen in the NMR spectrum. The dihedral
79

angle

for DCB 3507 (CASE A) should be small if hydrogens on C14 and C13a have

chiral carbons (13aS,14S); in order words, both hydrogens are “up” as shown in Figure
20 , probably less than 60°. If the stereochemistry on C14 and C13a would have a
configuration (13aR,14S) (CzASE B); then, the dihedral angle should be much larger
than 60°. The dihedral angle could be properly measured by a combination of several
methods, such as vicinal coupling constant 1H NMR (3J, H–C–C–H), the Karplus
equation, and molecular modeling.
2.3.8.2 Vicinal coupling constant analysis
The 3J coupling constant between the vicinal protons H14C and CH13a was
measured from 1H NMR spectroscopy at 300 MHz. The hydrogen on C14 appeared at
4.75 ppm as a doublet with a coupling constant J = 1.78 Hz, as shown in Figure 24. The
coupling constant for C13a could not be measured because it was highly overlapped by
other methylene hydrogens.
2.3.8.3 Karplus equation analysis
Vicinal coupling or 3J coupling is dependent upon the dihedral angle between the
nuclei. The magnitude of these couplings is generally the smallest when the torsion
angle is close to 90°, and largest (around J = 12 Hz) at angles of 0 and 180°. The
relationship between dihedral angle and coupling constant is known as the Karplus
relationship,20 and the following Figure 23 depicts a typical Karplus curve. For a
small, relatively rigid molecule, where a small coupling constant (1.78 Hz) is observed,
the small gauche angle as in Case A (Figure 22) is supported. This together with the
known configuration of C13a, leads one to assign the (S) configuration to C14.
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Figure 23: Karplus curve.
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The coupling constant J = 1.78 Hz was inserted into the Karplus equation, and it
gave a theoretical dihedral angle = 60.5°.
2.3.8.4 Molecular modeling (Tripos:Sybyl 8.0)
The application of molecular modeling using the program Tripos: SYBYL 8.0
(dynamic and MM4 minimization) was used to calculate the dihedral angles.
The drawing of the structure and use of molecular dynamics and MM4 to
minimize energy was the best approach. See Figure 25.
Table 9 resumes the predicted calculations from molecular modeling for DCB 3507.
Table 9: DC 3507 dihedral angle molecular modeling results
Structure
Dihedral angle (Ǻ)
Final steric energy (kcal/mol)
DCB 3507 from drawing

52.2

11.3392

A similar analysis to calculate dihedral angles was applied to DCB 3503 in
Chapter 1. Moreover, two additional structures were built using molecular modeling for
DCB 3507 with dihedral angles higher than 60° by increasing theoretical dynamics and
MM4 in SYBYL. These structures can be seen in Figures 23 and 26. Table 10 includes
data from DCB 3503, DCB 3507 and the two additional structures which were arranged
according to steric energy (from low to high).

Table 10: DCB 3507 and DCB 3503 dihedral angle molecular modeling results
Structure
1.DCB 3507
2.DCB 3503
5.DCB3507

Dihedral
(Ǻ)
52.2
51.1
69

angle Final
steric Figure
energy (kcal/mol)
11.3392
12.5425
25.408

25
8
26

The above table 10 gave us an important conclusion for the dihedral angle
approximation for either DCB 3503 or DCB 3507. It can be concluded that the dihedral
angle should be more than at 50.4° and less than 60°, because at 50° the steric energy
is almost double that 52.2°, and the dihedral angle should be no higher than 60°,
because the steric energy increases and the molecule starts to bend in the pyrrolidine
moiety as seen in Figures 25 and 26.
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Figure 25: Direct drawing and minimization molecular
modeling of compound 21.
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Figure 26: Direct drawing non planar DH = 69° molecular modeling compound 21.
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Chapter Three: Synthesis of DCB 3508
3.1. Statement of Problem
The synthesis of DCB 3508 was carried out to compare its activity with that of
DCB 3503 and DCB 3507. DCB 3508 is an analog of DCB 3503 in which the compound
is open at C10 of the phenanthrene system. See Figure 27.

Figure 27: Structure of DCB 3508
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3.2 Introduction
The idea of synthesizing DCB 3508 (Figure 27) came as a result of an
unexpected impurity found in the mass of DCB 3503 and an interest to find the
biological activity for an open-ring analog to DCB 3503. Compound

11

(DCB 3503)

had an exact mass of 409.19. When it was run using DART in positive-ion mode, it
showed the expected fragment [M+1]+ 410.197, but it also showed a peak at 412.213. It
came to my attention that it might be a side-product with higher polarity than

11,

because the development of TLC (2:0.5 CHCl3:CH3OH) showed an almost colorless
spot at the baseline of the TLC when it was stained with anysaldehyde–H2SO4. Also,
when running the impure

11 on HPLC, it showed a small peak that was very close to

the peak for DCB 3503.
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3.3 Results and discussion: Total synthesis of DCB 3508

Scheme 28: The synthetic route to DCB 3508.
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3.3.1 Synthesis of (S)-methyl-1-(2,3,6,7-tetramethoxyphenanthren-9-yl)
methyl)pyrrolidine-2-carboxylate (24)
The idea of coupling (S)-2-(methoxycarbonyl)pyrrolidinium chloride

6.1

to obtain

24

23 directly to

has been tried before without success using K2CO3 in DMF but

according to Fülep and co-workers,24 it could be accomplished using K2CO3 in acetone
with NaI at room temperature, and for my reaction it gave a 40-50% yield. A similar
alkylation was reported by Akué-Gédu1, and Vanecko and West32 suggested an
increase in temperature. This N-alkylation was a complete success only after heating
the solution at reflux for 48 hours; the product was produced in high yield and almost no
by-products were found.
It was interesting to indicate that Govindachari and co-workers33 tried a similar
alkylation without success under Marchini and Belleau’s conditions. Govindachari used
2,3,6,7-tetramethoxy-9-chloromethylphenanthrene with proline ester, dissolved them in
dry toluene, and refluxed with stirring for 20 h. However, he was successful in obtaining
the alkylation under the same conditions using prolinol, instead of proline ester.
Therefore, the following are conclusions.
1. The presence of Br or I as a leaving group in the starting material 6.1 determinated
the successful reaction. It seemed that this alkylation could not be completed if Cl was
the as leaving group.
2. According to Govindachari et al,33 the alkylation of 2,3,6,7-tetramethoxy-9chloromethylphenanthrene and proline ester undergoes a self-condensation of proline
ester much faster than reaction with the halide. This could have been avoided using a
better leaving group (Br or I)
3. The choice of solvent is important for the alkylation. Although DMF is a well-known
solvent for alkylations, it did not work for this case; however, acetone and dry toluene
was found to be useful.
4. The strength of the base had an important role for this alkylation. Potassium
carbonate is a weak base that is used for easy alkylations (good leaving groups and
strong nucleophiles). The use of strong bases, such as NaH, was not used to avoid self
alkylation of proline or elimination reaction of the halides.
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The structure of 24 was confirmed and characterized by mass spectrometry and
NMR spectroscopy. The exact molecular weight of 24 was 439.199, and it was found as
m/z 440.205 by AccuTOF-DART in the positive-ion mode. NMR spectroscopy supported
the structure. The most important prove of that the coupling reaction between 6.1 and
proline ester 23 was successful was the formation of the diastereotopic geminal
hydrogens (4.48, 3.53 ppm) at C1 for 24. It is also important to indicate that the starting
material 6.1 did not have diastereotopic hydrogens on C1; they were homotopic protons
giving one signal (4.99 ppm) (see Figure 28).
These geminal diasterotopic protons in 23 were also proved by 2D NMR
spectroscopy. The gCOSY spectrum showed a strong correlation between 4.48 and
3.53 ppm, which could indicate either geminal or vicinal hydrogens. The gHSQC
spetrum confirmed that they were geminal hydrogens, because these two hydrogens
(4.48, 3.53 ppm) were on the same F2 axis that correlated to only one carbon. The
NOESY spectrum also indicated a strong proximity through space.
The diastereotopic hydrogens on C1 in product 23 were also proved by J
coupling measurements. The diasterotopic hydrogens on C1 showed two distinct
chemicals shifts, but the same geminal coupling 2J (H,H) = 12.13 Hz (see Figure 29
and 30).

Figure 28: Diastereotopic hydrogens of 24.
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Figure 29: J coupling of compound 24 at 3.53 ppm.
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Figure 30: J coupling of compound 24 at 4.48 ppm.
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3.3.2 Synthesis of (S)-1(-((2,3,6,7-tetramethoxyphenanthren-9yl)methylpyrrolidin-2-yl)methanol (25)
DCB 3508 was synthesized in two easy ways. Both pathways require reduction
(see Scheme 29).
First pathway: Product 25 was accomplished by reduction of 7 with 2 equivalents of
LiAlH4 to reduce both the ester and lactam. This product 25 was obtained in high yield
without any side products.
Second pathway: Product 25 was accomplished by using 1 equivalent of LiAlH4 with 24
to obtain

25.

This reaction also gave a high yield of product, and TLC showed the

same Rf = 0.06 value as the impurity seen on the impure DCB 3503.
First reaction pathway:

Second reaction pathway:

Scheme 29: Synthesis of 25 by two routers.
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The structure of the impurity 25 was found using TLC, HPLC, MS, and NMR
spectroscopy. The total mass of the uncharged impurity had to be [M]: 411.20. The TLC
showed a spot almost on the TLC baseline that indicated a higher polarity than that for

11 (Rf = 0.13) (see Figure 31).

Using this information, several possible

structures were formulated that contained a [M] of 411.20 and had higher polarity than

11. The structure of 25 was the best candidate due to the perfect mass match and the
free alcohol that increased the polarity. The use of 1D and 2D NMR spectroscopy
(gCOSY, gHSQC, and NOESY) proved the structure.
The possibility to obtain chemically

25 as a by-product from the reduction of 11

using LiAlH4 could not be reasonable. It was possible that unreacted compound

8

was

carried along with the product during the last two steps of the synthetic path, finally
being reduced with LiAlH4. It is important to indicate that compound

8

was observed on

TLC in very small quantities at Rf = 0. HPLC was then used to find any possible byproduct that might not be seen on TLC. The possible reaction route for this by-product is
proposed in the Scheme 30.

Figure 31: Rf values for compound 11 and 25.
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Scheme 30: Reaction route for by-product 25.

Compound 25 was synthesized in order to be assayed in the 60-cell
screen for antitumor activity at the National Cancer Institute. This compound was an
analog of DCB 3503 with potential anti-cancer properties. Unfortunately, this compound
25 was not as potent as DCB 3503.
Similar polar phenanthrene-based tylophorine derivatives containing a prolinol
were synthesized and evaluated as potential antitumor agent by Wei and coworkers.34(Figure 32). These structures (B and D) are shown below.
These compounds were evaluated for cytotoxic activity against the A549 human
cell cancer line as described in the paper by Wei and co-workers.

34

It is important to

indicate that compound A and D showed the highest potency with IC50 values of 0.27
and 0.16 μM, respectively, which are currently used as anticancer drugs.
These compounds contained structural similarities to DCB 3508.

A core

phenanthrene structure with an open chain at C10, a hydroxyl terminal group in the
pyrrolidine structure, a methoxy group on C6, and 1,3-dioxolane moiety groups
compared to methoxy substituents in the DCB 3508
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Figure 32: Tylophorine derivatives containing prolinol.

Table 11: Partial table from the paper of Wei et al29
Compound
IC50 (μM)
A

0.27

B

0.7

C

0.5

D

0.16
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Chapter Four: Synthesis of DCB 3509
4.1 Statement of Problem
We obtained the biological results from DCB 3503, 3507, and 3508 conducted at
the NCI. These data were plotted in the molecular modeling program, CoMFA, to predict
biological activity for a range of analogs. CoMFA predicted high biological activity for
DCB 3509 (see Figure 33); therefore, it was synthesized.

Figure 33: Structure of DCB 3509.

4.2 Introduction
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Synthesis of DCB 3509 came from an interest to explore the biological activity of
a DCB 3503 analogs with a short aliphatic chain with a hydroxyl group at the end on the
aromatic C3 position. DCB 3509 will be submitted soon for biological analysis at the
National Cancer Institute. Meanwhile, CoMFA, a molecular modeling program, predicted
that DCB 3509 could be highly potent.

4.2 Results and discussion: Total synthesis of 3509
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Scheme 31: The synthetic route to DCB 3509.
Scheme 34, cont’d.
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Scheme 34, cont’d
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The total synthesis of DCB 3506 or 36, as described in Scheme 34, has been
previously accomplished by Mr. Conrad Kaczmarek in the laboratory of Dr. David Baker
in 2004. The discussion of DCB 3506 can be found in his MS Thesis. Therefore, since it
was not an original work by this author, I did not include any chemical discussion in this
dissertation. However, the synthesis of 36 is covered in the experimental section in this
dissertation.
4.3.1 Synthesis of Preparation of (13aS, 14S)-3-(3-hydroxypropoxy)-2,6,7trimethoxy-9,11,12,13,13a,14-hexahydrodibenzo[f,h]pyrroolo[1,2-b]isoquinolin-14ol (37)
The synthesis of 37 was accomplished by an alkylation of 36 by 3bromopropanol using K2CO3 as base. The alkylation was run at 70 °C for 48 hours,
because after only 24 hours the alkylation was incomplete, and some starting material
was detected by mass spectroscopy. If this was the case, 0.5 molecular equivalents of
3-bromopropanol linker arm and K2CO3 was added which reflux overnight to complete
the reaction, which solved the problem.
This alkylation gave an exclusive substitution at the phenolic oxygen on C3 as
shown in Scheme 32. Because the phenol is a stronger acid than the secondary OH on
C14 a mild base (K2CO3) was used to achieve stereoselectivity; therefore, strong bases
such as NaH and hydroxides of alkali metals and alkaline earth metals like NaOH and
Ca(OH)2 were avoided.

Scheme 32: Alkylation of 36 to obtain 37.
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The exclusive substitution on the phenol instead of the secondary alcohol was
proved by mass spectrometry and NMR spectroscopy (Figure 34).

Figure 34: Possible substitutions for compound 37.
Mass spectrometry (AccuTOF-DART in the positive-ion mode) of 37 indicated an
exact mass of [M+1]+ = 454.215 and molecular fragment [M-OH]+ = 436.211 that
corresponded to the ionization of the secondary alcohol. In the event that the secondary
alcohol was alkylated by the 3-bromopropanol, the exact mass would be 453.215, that
is the same as 37, but it would leave a free phenol that is easier to fragment due to the
aromatic ring, and be detected than a primary alcohol; therefore, its expected fragment
[M-OH]+ = 437.220, was not found. The molecular ion of the fragmented phenol was
stabilized by the ring, thus increasing the probability of its appearance than a primary
alcohol.35 This ion fragment 437.220 was not detected by mass spectrometry; therefore,
there is a high probability that alkylation went exclusively to the phenol.
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There was another product that could be produced. A potential quaternary amine
could be formed if the tertiary amine alkylated the 3-bromopropanol, as shown in
Scheme 36.

Scheme 33: Alkylation of 36 at the tertiary amine.
The possibility of forming a quaternary amine over alkylation in the phenol is low.
This cationic compound would be unstable and undetectable by mass spectrometry,
because DART–ESI in positive/negative mode does not detect cationic/anionic
compounds. In order to easily rule out possible this side-product, we turned to NMR
spectroscopy. The 1H NMR spectrum clearly showed the methylene triplet at 4.22 ppm
with an integration of 2H that corresponded to C1 on 37 (Figure 35). The downfield
chemical shift of C1 at 4.22 ppm was predicted due to the deshielding effect of the
oxygen’s lone pair electrons. On the other hand, if the formation of a quaternary amine
would exist, it would give a methylene multiplet for C1 with an expected chemical shift at
3.22 ppm with an integration of 2. This chemical shift or multiplet was not seen in the 1H
NMR spectrum; moreover, the phenolic proton chemical shift around 5.35 ppm was not
present either.

Figure 35: Chemical shifts for alkylation of 37.
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Figure 36: Molecular modeling structure for compound 37.
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Chapter Five: Synthesis of Biotinylated Tylophorine Analog
5.1 Statement of Problem
Another project was the synthesis of a tylophorine attached to an aliphatic chain
of 6 carbons with a biotin 41, to help identify the protein receptor(s) in the cancer cell.
Biotin is a naturally occurring compound that binds with high affinity and specifity to
avidin and streptavin proteins. The bond formation between biotin and avidin is rapid
and unaffected by most extremes of pH, organic solvents, and denaturaturing agents.
These conditions are ideal for the construction of a robust biological probe.
We were aware of the strength and specificity of the avidin–biotin complex;
therefore, these biotin and linker arms are the best tools that will help us to understand
the reaction mechanism of our tylophorine (DCB-3503) in the cell. This biological
research will be done by our collaborator, Dr. Y.-C. Cheng at Yale University School of
Medicine.
One of the main problems would be the attachment of biotin through a peptide
bond. The attachment was considered through different intermediates in the synthetic
route.
Another important problem would be the nucleophile at the end of the aliphatic
chain. The nucleophile will have to be an amino group, but other groups were also
analyzed.

Figure 37: Biotinylated tylophorine analog structure.
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5.2 Introduction
The biotinylation of DCB 3503 via a tether was made to do studies of the
molecular mechanism of DCB 3503 in cancer cells at the laboratory of Dr. Y. C. Cheng
at Yale University.
The remarkably high affinity (Kd = 10-5 M-1) of the vitamin biotin for the
glycoprotein avidin has been used as a powerful tool in a wide variety of bioanalytical
applications. In the past, researches have routinely employed a six-atom (amino
caprolyl) linker chain between the biotin and active compounds in vatious chemical
application with great success. Following this idea, our lab decided to link our DCB 3503
with a tether, in this case a saturated chain of 6 carbons to biotin.
The author decided to attach a linker not higher than 6 carbons, because of
possible lipophilicity problems inside the cell. Also a linker with less than 4 carbons has
been reported as unsuccessful on experiments. Therefore, a 6 carbon member link was
considered ideal.
This synthesis turned out to be challenging due to the functional groups in DCB
3506 and tendency of DCB 3506 to undergo further reactions. Several synthetic routes
have been tried; two routes reached the final step to obtain the final compound, but
unfortunately

failed

in
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the

last

step.

5.3 Results and discussion: Total synthesis of a biotinylated
tylophorine analog.

Scheme 34: The synthetic route to synthesis of biotynilated tylophirine analog.
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5.3.1 Synthesis of (13aS, 14S)-3-(6-bromohexyloxy)-14-hydroxy-2,6,7trimethoxy-12,13,13a,14-tetrahydrodibenzo[f,h]pyrrolo[1,2b]isoquinolin-11(9H)-one (38)
The synthesis of 38 was achieved under the same conditions as those for 37.
The alkylation required a commercially available 1,6-dibromohexane to be used as
linker arm, the intermediate 35 tylophorine analog, and K2CO3 as a weak base.
This reaction was run at 75 °C for 48 hours. It was also noticed that for only 24
hours the reaction was incomplete, because mass spectrometry indicated presence of
starting material. In order to solve this problem, 0.5 equivalents of 1,6-dibromohexane
and K2CO3 were added to the solution with reflux overnight. At room temperature, the
solvent was vacuum evaporated at 35 °C until it turned into a mixed solid/liquid phase.
Then 1:2:1 EtOAc:hexanes:Et2O was added , and the solution was left stirring for 30
minutes at room temperature, and product 38 precipitated as yellow powder in high
yield.
The presence of the terminal Br gave the characteristic mass peaks for halogen
compounds. It is known, that a compound that contain one bromine atom would have an
M+2 peak almost equal in intensity to the molecular ion because of the presence of a
molecular ion containing the two isotopes
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Br and

81

Br in an approximately ratio 1:1

(50.5:49.5). This means that a compound containing 1 bromine atom will have two
peaks in the molecular ion region as shown in Figure 38.

Figure 38: Characteristic peak intensities for a monobrominated compound
In compound 38, the exact molecular mass was [M] = 571.157. The protonated
(including a hydrogen) ion 38 [M+1]+ = 572.167 and [M+2]+ = 574.167 with almost two
high-intensity peaks were found in the mass spectrum. The ion fragment [M-OH]+ =
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554.171, for which the theoretical exact mass is [M-OH]+ = 554.154 was also present.
Therefore, mass spectrometry of 38 proved the presence of the alkylated compound.
(See Figure 40).
The NMR characterization of 38 also corresponded to the predicted chemical
shifts. The most important peak found in this structure was the aliphatic methylene
hydrogens on C1, see Figure 36, because these two hydrogens would have an unique
chemical shift around 4.24 ppm due to the presence of oxygen, a triplet multiplicity, and
an integration of 2H. On the other hand, the methylene hydrogens on C6 had a
chemical shift around 3.50 ppm as expected due to the presence of bromine.
There are two other possibilities for alkylation, but these were discarded. The first
possibility would be the alkylation of the secondary alcohol, but primary alcohols are
weak nucleophiles and could not compete with phenol anion which is a stronger
nucleophile. The second possibility would be the alkylation of the nitrogen in the amide
group. This possibility was immediately discarded, because the amide group is of very
low nucleophilicity.

Figure 39: Compound 38.
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Figure 40: Mass spectrum of compound 38
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5.3.2 Synthesis of (13aS,14S)-3-(6-azidohexyloxy)-14-hydroxy-2.6.7trimethoxy-12,13,13a,14-tetrahydrobibenzo[f,h]pyrrolo[1,2b]isoquinolin-11(9H)-one (39)
The synthesis of product 39 was achieved by a displacement of the bromo group
of 38 by an azido group. This simple transformation was a successful reaction that gave
39 in high yield and as a stable product.
The exact molecular weight of 39 was proved by AccuTOF–DART position-ion
mode mass spectrometry. The exact mass was [M] = 534.248, and its experimental
mass was found [M+1]+ = 535.253, with an ion fragment [M-OH]+ = 517.237, for which
the theoretical fragment mass is [M-OH]+ = 517.245. Neither the starting material 38 nor
its ion fragments were present in the mass spectrum. The mass spectrum is shown in
Figure 42.
The TLC plate of 39 had a smaller Rf than 38. This smaller Rf was expected,
since the brominated 38 is a little less polar than the azide 39 as seen on Figure 41.

Figure 41: Rf values for compound 38 and 39.
The complete characterization was done by NMR spectroscopy. The product 39
was proved by using 1D, 2D (gCOSY, gHSQC, and NOESY). All the correlations and
chemical shifts were found in the expected chemical shifts.
It was noticed that product 39 was highly stable under light, heat (40–50 °C),
solvents, and air. It was easy to be detected under UV light and could be purified by
silica gel column chromatography, with the solvent system 2:1:0.5 CHCl3:EtOAc:MeOH.
The solvent system needed EtOAc to slow the column to separate any small traces of
DMF solvent that high vacuum could not evaporate.
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Figure 42: Mass spectrum of compound 39.
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5.3.3 Synthesis of (13aS,14S)-3-(6-aminohexyloxy)-2,6,7-trimethoxy9,11,12,13,13a,14-hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-14ol (40)
The synthesis of 40 was performed by reduction of the azide and lactam group
from the intermediate 39 with 2 equivalents of LiAlH4. The double reduction reaction
transformed the azide into a primary amine and reduced the cyclic amide group or
lactam into a tertiary amine. In order to verify the product 40, the following tests were
done:
1.

Ninhydrin stain test: This functional group-selective ninhydrin was used to

detect the presence of a primary amine on TLC chromatography, which showed a
positive result with a big and strong purple-blue spot that stained almost immediately at
the bottom of the TLC plate (after heating with a heat gun). A separate TLC plate was
stained with anysaldehyde–H2SO4 to detect any presence of starting material 39. No
starting material or side-product was found on TLC. Primary aliphatic amines bind
strongly to silica gel, so primary amines would not be expected to migrate on silica gel
TLC; therefore, the primary amine compound stayed at the bottom. This test also
showed positive, because the purple stain spot was at the base of the silica gel plate. A
representative picture of TLC plate of starting material 39 with Rf = 0.25 on
anisaldehyde, and product 40 with Rf = 0 on ninhydrin is shown in Figure 43.

Figure 43: Rf values for 39 and 40.
2.

Mass spectrometry: The molecular weight was determinated using

AccuTOF–DART in the positive-ion mode. The exact mass of 40 with addition of H+ was
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[M+1]+ = 494.278. This protonated product and ion fragment [M-OH]+ = 477.275 were
detected as high-intensity peaks on mass spectrometry, as shown in Figure 45.
The following Table 12 shows the theoretical mass calculation and experimental
mass detected on AccuTOF DART positive-ion mode for the [M+1]+ and [M-OH]+.

Table 12: Compound 40 theoretical and experimental mass
Product/fragment
Theoretical mass
Experimental mass
[M+1]+

495.278

495.279

[M-OH]+

477.275

477.271

The following structures, Figure 44, represent 40 as product [M], and its ion
fragment [M-OH]+ found on mass spectroscopy.

Figure 44: Molecular weight and fragment ion for compound 40.
It is important to indicate that no starting material 39 [M+1]+ = 535.248 or its ion
fragment [M-OH]+ = 517.25 were detected on mass spectrometry.
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Figure 45: Mass spectrum of compound 40.
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3. HPLC: The HPLC showed a fairly clean crude product with a major peak with
high intensity that represented the product.
Unfortunately, this product was highly sensitive to heat and unstable. It was
noticed that during vacuum evaporation the product decomposed at 35 °C, turning from
a yellowish solution to a brownish oily product. Therefore, the solvent had to be removed
using vacuum evaporation at room temperature. This product seemed to decompose
after few hours of being made. It is known by experience that after overnight in the
vacuum pump the product would not show the same high intensity peaks on the AccutofDART positive-ion mode, and the intensity of the ninhydrin spot did not have the same
strong purple stain. Under these circumstances, this amine had to be directly used for
the next reaction without any purification.
Changing the conditions for the reduction reaction were tried in order to improve
the yield and quality of product.
1. The molecular equivalents of LiAlH4 were reduced, since the reduction
required only two molecular equivalents of LiAlH4 to reduce the azide and lactam group,
only 25% of the LiAlH4 was taken out to reduce the azide and lactam group, but the
reaction still showed presence of starting material.
2. The duration of the reaction was reduced from overnight to six and three
hours respectively, in different reactions, but the same sensitive product always resulted.
Then, three different quenching methods were used to improve the stability of the
product:
1. EtOAc and 2 N HCl: Ethyl acetate is known to quench LiAlH 4 at -10 °C, but
addition of 2 N HCl gave lower yield, because it probably protonated the primary amine
transforming into an aminium group (

), which during organic/aqueous extraction

went to the aqueous phase.
2. EtOAc and Na2SO4∙10H2O: Addition of Na2SO4∙10H2O gave a better yield then
the previous method (EtOAc and 2 N HCl), but four hours were required to decompose
the LiAlH4, because with any extended time in EtOAc the solution and product would
decompose. An overnight quenching was expected to lower the yield.
3. EtOAc and 3 M NaOH: Addition of 3 M NaOH gave the highest yield, but the
amine was still sensitive to heat and decomposed upon standing in solution.
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Under these circumstances, the possibility to eliminate a reduction reaction using
LiAlH4 in the reaction pathway was analyzed. Therefore, the following route was applied
(see Scheme 35).

Scheme 35: Alternative route to obtain 44.
In order to eliminate the reduction reaction of the azide group using LiAlH4,
product 36 (DCB 3506) was used to successfully obtain 42 in an alkylation reaction.
Then, a transformation reaction from Br to N3 was also carried out in high yield. The
reduction of the azido group was achieved using hydrogenation under pressure (50 psi)
using two different catalysts: Pd-C or PtO2 (Adams’ catalyst). Unfortunately, product 44
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was still as sensitive and unstable as 40. Therefore, the next step had to be carried out
without purification.

5.3.4 Synthesis of N-(6-((13aS,14S-14-hydroxy-2,6,7-trimethoxy9,11,12,13,13a,14-hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-3yloxy)hexyl)-5-((3aS,4aS,6aR)-2-oxohexahydro-1H-thieno[3,4d]imidazol-4-yl)pentanamide (41)
In order to link biotin via a peptide bond to the primary amine 40, (HATU) or
(HBTU) (see Figure 46) was used as a coupling reagent. Both of these coupling
reagents were chosen because either was successful for generating the peptide bond.
Other coupling reagents were tried, such as DCC (1,3-dicyclohexylcarbodiimide), DIC
(diisopropylcarbodiimide), and EDC (ethyldimethylaminopropylcarbodiimide), but these
were either unsuccessful or gave the product in low yield.

Figure 46: Chemical structure for HBTU, DCC, DIC, and EDC.
The carbodiimide activated ester is very reactive. In the case of slowly reacting
nucleophiles, rearrangement is a common side reaction, which might have formed the
stable acyl urea (see Scheme 36). Since the coupling reagent was left stirring overnight
with biotin, this could be the reason for the unsuccessful reactions using DCC, DIC, and
EDC. Later it was found that this problem could be avoided by adding HOBt.
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Scheme 36: The carbodiimide activated ester rearrangement.
There exits a large number of coupling reagents, but two are more popular,
HBTU and HATU. These analogous compound HATU and HBTU were used to form the
peptide bond. The following reactions represent the mechanism reaction to obtain 41 in
either case (see Scheme 37 and 38)

Scheme 37: Mechanism using HATU.
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Scheme 38: Mechanism using HBTU.
Mass spectrometry:
1. AccuTOF-DART in either the positive- or negative-ion mode did not detect 41.
This is expected due to the high molecular mass M = 720.356 and the presence
of biotin. Starting material 40 was not detected either.
2. Quatro II spectromer: The Waters Quattro II is a triple quadrupole mass
spectrometer. The Quattro II is equipped with an electrospray-ionization (ESI)
source and an atmospheric pressure chemical ionization (APCI) source. It is
integrated with an Agilent 1050 HPLC system. The Quatro II detected the 41
mass [M+1]+ = 721.214 and its ion fragment [M-OH]+ = 703.191 with high
intensity, as seen in Figure 47 Although, it is known that the Quatro II does not
provide high-resolution MS, it showed the expected [M+1] ion.
3. MALDI-TOF MS: This instrument provided high-resolution, and the peaks could
be calibrated with an internal calibration standard. MALDI detected the [M] =
720.3385 and sodium adduct [M + Na]+ = 743.3406 with a ppm error of 6.7 ppm
(see Figure 48), and 2.6 ppm (see Figure 49) on different occasions. According
to our instrument specifications; the limit of error for the MALDI-TOF MS should
not be higher than 10 ppm.
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It is important to indicate that these spectra show higher peaks at 795.5387,
853.5866, 911.6284, 969.6696 that belonged to the internal calibration standard that
was mixed with 41 in order to calibrate the peaks.
Table 13 shows the summary of molecular masses for the theoretical and experimental
results.
The ppm error was calculated with the following formula given by the mass
spectroscopy center.
Mass Accuracy
∆m = mtheoretical - mmeasured
ppm Error = (∆m/mtheoretical) x 106
Example:
∆m = 743.345 – 743.347 = 0.002
ppm Error = (0.002 / 743.345) x 106 = 2.690

Table 13: Theoretical and experimental mass for compound 40
Theoretical mass (m/z)
Experimental mass (m/z)
Product 41
[M]

720.356

720.338

[M – OH]+

703.353

703.343

[M + Na]+

743.345

743.347
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The crude product 41 was run on the HPLC using a reversed-phase column
(C18). This separation indicated the number byproducts and starting materials in the
crude product. Since the HPLC spectrum indicated at least 7 peaks, a precipitation of
the pure product was tried using MeOH:Et2O (10:1). A yellowish solid precipitated
overnight in the freezer. This solid was run in the HPLC using the method Tylo 79:21
(79% MeOH and 21% H2O) that demonstrated the best separation of peaks. The HPLC
results showed 6 peaks (see Figure 50). Since it is a novel compound, the author did
not know which peak belonged to product 41. In order to solve this problem, a HPLC–
MS separation was used (using the same separation method Tylo 79:21 and reversedphase column (C18) to find which peak belonged to product 41. Product 41 was the fifth
peak that came out from 4.06 to 5.08 minutes (see Figure 51), with molecular weight
[M+1]+ = 721.13. Using these important results, the next step will be used a Biotage
instrument with reversed-phase column to separate the product 41.
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Figure 47: QUATRO II mass spectrum for compound 41.
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Figure 48: MALDI mass spectrum with 6.7 ppm error for compound 41.
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Figure 49: MALDI mass spectrum with 2.6 ppm error for compound 41.
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Figure 50: HPLC results for compound 41 with method 79:21 (MeOH:H2O).
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Figure 51: HPLC–mass spectrometer results for compound 41.

130

Figure 52: Molecular modeling of the structure for compound 41.
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CHAPTER 6: Evaluation of the Tylophorine Analogs in the
National Cancer Institute’s screen.
6.1 Statement of Problem
The goal was to have the National Cancer Institute evaluate synthetic analogs to
DCB 3503 in their 60-cell line panel of human-derived cancer cells. Structure–activity
relationships, which are important in rational design of analogs, are expected to
emerge.

6.2. Background.
6.2.1. Screening
The Developmental Therapeutics Program (DTP) of the National Cancer Institute
(NCI) conducts a screening program in vitro and in vivo for potential anti-cancer
compounds. The main purpose of this project is to identify and evaluate novel chemical
compounds and to define, to a limited extent, their mechanism of action.
6.2.2. In Vitro testing cells
The In Vitro Cell Line Screening Project (IVCLSP) was developed in 1990 at the
NCI. This project routinely screens 60 different human tumor cell lines with subpanels
that include the following: lung cancer, colon cancer, breast cancer, ovarian cancer,
leukemia, renal cancer, melanoma, prostate cancer, and CNS cancer (central nervous
system). The goal was to evaluate synthetic compounds or natural product samples to
observe any selective growth inhibition or cell killing for any tumor cell indicated above.
The biological results are represented by algorithms, which can be indicative of
certain mechanisms of action from a test compound. These algorithms could indicate a
range of compounds that might interact with specific molecular targets. Analysis of this
data can be performed by a program called COMPARE.
6.2.3. Concentrations parameters
The NCI used these parameters: GI50, TGI, and LC50 mainly as algorithms to
represent the results from each cancer cell screened.
GI50: These data represent the drug sensitivity. In other words, GI 50 indicates the
concentrations required to inhibit cancer cell growth by 50%. The GI 50 is a measure of
the growth inhibitory power of the test agent.
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TGI: These data signify the cytostatic effect. In other words, TGI is a measure of the
suppression of cellular growth or multiplication.
LC50: These data indicate the lethal concentration that kills cancer cells by 50%.
6.2.4 The Mean Graph
The mean graph represents the in vitro results that emphasize differential results
on various tumor cell lines.
The mean graph plot the positive and negative results from a set of GI 50, TGI,
and LC50 values. The vertical line represents the mean response of the cell lines.
Positive and negative results are plotted along the vertical line. Results on the right
represented cellular sensitivities of the cell that exceed the mean. Results on the left
represent cell line sensitivities of the cell less than the average value.

6.3 DCB 3503 cytotoxic analysis and structure–activity relationships
Evaluation of DCB 3503 in the National Cancer Institute’s tumor screen showed
a uniform and potent inhibition of cell growth in all 60 cell lines (GI 50 ~ 10-8 M) as seen in
Figures 51 and 53, with notable selectivity toward several refractory cell lines, including
melanoma and colon cancer cell lines based on GI50 values.
The overall activity of DCB 3503 can be seen in Figure 50. DCB 3503 dose–
response curves (all cell lines) showed a concise drop for all cancer cells at 10-08 M. The
direction of that curve is important, because it indicates that almost all cancer cells were
inhibited to 50% growth at 10-08 M. It is important to indicate that DCB 3503 has the
lowest GI50 among all our DCB analogs; therefore, it holds the highest activity. The
following Table 14 shows some of the relevant cancer cell lines that were inhibited by
DCB 3503. The complete table can be seen in Figures 53, 54, 55, and 56.
Table 14: DCB 3503 some relevant cell line and growth percent
Panel/Cell Line
GI50 (E-08)
Colon Cancer (COLO 205)

1.00

Renal Cancer (786-0)

1.00

Melanoma (SK-MEL-2)

1.00

Melanoma (SK-MEL-5)

1.00

Additionally, Dr. Gao did additional biological testing of DCB 3503 at Yale
University. DCB 3503 also exerted potent growth-inhibitory effects against HepG2
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(human hepatocellular carcinoma) and KB (human nasopharyngeal carcinoma) cell
line’s.3
Treatment of nude mice bearing HepG2 tumor xenografts by i.p. injections of
DCB 3503 at 6 mg/kg every 8 h on days 0 and 3 resulted in significant tumor growth
suppression (P < 0.0001). Unlike conventional antitumor drugs, 3 μM DCB 3503 did not
cause DNA breaks or apoptosis in HepG2 cells.
This tylophorine analog is a member of a unique class of antitumor compounds
that have a mode of action different from known antitumor drugs. Early mechanistic
studies demonstrated that tylophorine analogs irreversibly inhibit protein synthesis at
the elongation stage of the translation cycle.

The phenanthroindolizidine alkaloids

tylophorine have been shown to be powerful inhibitors of the incorporation of leucine
into protein in Ehrlich ascites-tumor cells (a transplantable, poorly differentiated
malignant tumor which appeared originally as a spontaneous breast carcinoma in mice.
It grows in both solid and ascitic forms by 50% at 10-6 M, but does not inhibit the
incorporation of uracil into nucleic acids at 10-5 M.6
In 1960, tylocrebine was advanced to clinical trial but failed due to its significant
CNS toxicity, manifested as disorientation and ataxia. Dr. Staerk proposed to synthesize
more polar analogs that could minimize the side effects, because these polar analogs
would not pass through the blood–brain barrier. Therefore, DCB 3503 is an excellent
candidate to overcome this problem, because it contains a secondary alcohol at C14,
which provides polarity (see Figure 53.

Figure 53: Structures of tylophorine, tylocrebine, and DCB 3503.
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Figure 54: DCB 3503 mean graph.
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Figure 55: DCB 3503 dose–response curves (all cell lines).
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e 57: DCB 3503 in-vitro testing results.
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6.4 DCB 3507 cytotoxic analysis and structure–activity relationships
Evaluation of DCB 3507 for the National Cancer Institute tumor screen showed a
potent inhibition of cell growth in some of the cell lines with an overall GI 50 ~10-6 M, with
notable selectivity toward several refractory cell lines in melanoma and renal cancer
(see Table 15).
Table 15: DCB 3507 relevant cell line, GI50, and growth percent
Panel/Cell Line
GI50 E-06
Growth Percent
Colon Cancer (COLO 205) 1.12
-54.78
Renal Cancer (786-0)
3.58
-56.30
Melanoma (SK-MEL-2)
3.03
-54.67
Melanoma (SK-MEL-5)
1.07
-70.34
Even though DCB 3507 showed high activity, it has lower activity when
compared to DCB 3503. DCB 3507 presented interesting activity with melanoma1 and
renal cancer at GI50 = 10-06 M, but DCB 3503 had a GI50 = 10-08 M against the same
tumor.
DCB 3507 clearly showed its lower activity in the graph: dose–response curves
(all cell lines) in Figure 57, 58, 59, 60, and 61. These graphs indicated straight inactivity
lines from 10-08 M until 10-06 M, only after 10-06 M inhibition of cancer cells start to grow
by an overall drop of cell lines. Due to this lower activity any further analysis or
modification for DCB 3507 has been teminated.
Although DCB 3507 had low reactivity, it gave positive and conclusive structure–
activity relationship (SAR) results.
First: The DCB 3503 analog must have at least four methoxy groups to increase
biological activity. The exact positions could be in R2, R3 for the top part of the
phenanthrene ring, and R5,R6 or R6,R7 for the bottom part of the aromatic system as
seen in Figure 58. The possibility to increase activity in R5, R6 analog instead of an
analog substituted in the R6, R7 position was indicated by tylocrebine’s high activity,
because it had the methoxy groups in R5, R6 position. However, little is known about
the precise mode of action of these compounds, and similar structures may not have
similar modes of action, a point recently made in the study by Y.-C. Cheng and coworkers. So far, we had used methoxy groups, but it would be interesting to make
ethoxy groups or long/short aliphatic chains with polar functional groups at the end
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replacing methoxy groups to study their biological activities. Therefore, DCB 3508 has
been synthesized.
It is likely that the ring’s electron density affects the binding at the indolizidine
system, which is more likely the pharmacophore.
It is important to indicate that all these biological data are investigation about potency,
but these data gave limited information on any results any adverse effects. At this time,
we do not know if DCB 3503 is more toxic in vivo or is able to produce more negative
side effects in the human body than DCB 3507. Our main goal is both to increase
potency and decrease adverse effects, such as addictive properties.

Figure 58: Tylophorine derivative with R substituents
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Figure 59: DCB 3507 One–dose mean graph.
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Figure 60: DCB 3507 dose–response curves (all cell lines).
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Figure 61: DCB 3507 dose–response curves (by cell line).

144

Figure 62: DCB 3507 In-vitro testing results.
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Figure 63: DCB 3507 mean graphs.
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6.5 DCB 3508 cytotoxic analysis and structure–activity relationships
Evaluation of DCB 3508 in the National Cancer Institute tumor screen did not
show potent inhibition of cell growth in the cell lines (GI50 ~10-5 M) (see figure 64) with
an interesting selectivity toward several refractory cell lines in leukemia, (see Table 16).

Table 16: DCB 3508 relevant cell line and growth percent
Panel/Cell Line
Growth Percent
Leukemia (MOLT-4)

-46.10

Leukemia (SR)

-50.57

Renal Cancer (ACHN)

-50.09

Renal Cancer (SN12C)

-49.37

Melanoma (LOX IMVI)

-46.03

This low reactivity allowed one draw certain conclusions about structure–activity
relationships (SAR).
First: the tylophorine system must be complete and have a closed cyclohexyl ring (see
Scheme 42) in order to be active (GI50 , 10-6 M, for example).

Figure 64: DCB 3503 and DCB 3508 structures.
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Second: there may be a configurational dependence at C14 for anticancer activity. The
(S)-epimer (DCB 3503) is more active than the (R)-epimer (DCB 3501), and the activity
of DCB 3507, whose-OH group is relatively free to rotate and assume a variety of
conformations, is further diminished.
Given the fast that the 14-OH group in DCB 3503 increases in vivo activity over
that of tylophorine (DCB 3500), which lacks a C14 hydroxy group.
The 14-OH could be modified by its bioisosteres, that is functional groups with
similar chemical activity and as consequence similar biological activity. The possible
bioesteres are CH3, NH2, F, and Cl.36 The chiral C14 carbon with stereochemistry (S)
sould not be modified, because it was proven that (S) chiral was more active than (R).
The 5-membered ring could also be modified (without removing the N) by incorporing a
6-membered ring.
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Figure 65: DCB 3508 One–dose mean graph.
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6.6 DCB 3509 cytotoxic analysis and structure–activity relationships.
The biological activity of DCB 3509 will be obtained from NCI within 3-4 months.
The potency has been predicted to be high by the CoMFA molecular modeling program,
using structures and biological data from DCB 3503, DCB 3507, and DCB 3508. These
considerations, the author decided to synthesize DCB 3509 with a short saturated
straight chain of three carbons with a polar hydroxyl group at the end (see Figure 66).
The length of the chain will be varied if DCB 3509 turns out to be highly active.

Figure 66: Strucutre of DCB 3509.
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6.7 Synthesis of biotinylated tylophorine analog cytotoxic analysis
and structure–activity relationship
The biological activity of this biotinylated tylophorine analog will be available in a
near future. Dr. Y. -C Cheng at Yale University will be conducting the biological studies.
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6.6 Conclusions
The improved synthesis of DCB 3503 has provided the means to produce DCB
3503 in 200–400 mg amount in one batch, which in the past was limited to 60 mg in one
batch. The most expensive chemicals were replaced with cheaper reagents that were
commercially available. These reactions gave also higher yields and were suitable for at
least a 4 g scale. These new reactions or improved steps eliminated the need to run
chromatography columns to purify products; therefore, the use of expensive solvents
such as EtOAc and hexanes were not needed to purify scale-up reactions up to 4 g.
The syntheses of DCB 3503, DCB 3506, DCB 3507, DCB 3508, DCB 3509, and
the biotinylated chain to DCB 3506 were carried out to develop the structure–activity
relationships and to study the mechanism of reaction with tumor cells. We were also
interested in pharmacokinetic, and pharmacodynamics in the cellular level to identify the
pharmacophore that binds to cancer cells.
I. Structure–Activity Relationships.
All compounds were evaluated in the 60-cell panel of human-derived tumor cells
at the National Cancer Institute. These results offered important information about their
structure–activity relationships (SAR). These analogs were modified by replacing
methoxy groups (DCB 3503) with hydrogen (DCB 3507), opening cyclic rings (DCB
3508), and attaching a short aliphatic chain (DCB 3509). These modifications either
increased or lowered activity.
Tylophorine is considered a structurally specific drug. These drugs, which most
drugs are, act with specific sites such as a protein receptor or enzyme. Tylophorine’s
activity and potency was shown to be susceptible to small changes in chemical
structure. Therefore, changing chemical groups gave us an idea what groups were
responsible for evoking a biological effect in the living organism.
II. Pharmacokinetics.
It is known that more than three-quarters of drug candidates do not make it to
clinical trials because of problems with pharmacokinetics in animals. 37 Only less than
10% of drug candidates in clinical trials become marketed products. One of the main
obstacles is pharmacokinetic problems, which manifest themselves as poor oral
bioavailability or short plasma half-life. Low water solubility of a compound (high
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lipophilicity) is a limiting factor in oral bioavailability, and highly lipophilic compounds are
easily metabolized or tend to bind to plasma proteins. Moreover, low lipophilicity leads
to poor permeability through membranes. Therefore, we need to balance the
pharmacokinetic properties of the tylophorine analogs to modify and increase potency.
Pharmacokinetics is important for drug discovery, and in 1997 Lipinski proposed
“the rule of five” as guide to improve oral bioavailability during modifications. It has been
shown that more than 90% of the compounds with two or more of these points will have
poor oral absorption or distribution properties:
1. Molecular weight is >500.
2. The log P is < 5.
3. There are more than 5 H-bond donors.
4. There are more than 10 H-bond acceptors.

Figure 67: DCB 3503, 3507, 3508, and 3509.
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Table 17: Lipinski’s “rule of five” applied to DCB analogs
DCB 3503

DCB 3507

DCB 3508

DCB 3509

Molecular weight

409.189

349.168

453.215

411.205

Log P

2.92

3.18

2.51

3.24

5 H-bond donors

1

1

1

2

10 H-bond acceptors 6

4

6

7

Analysis of Lipinski’s “rule of five” applied to DCBs can be seen in Table 17. The
molecular weight for DCB 3503, 3507 3508, and 3509 are all below 500. As mentioned
before, the side chain of DCB 3509 could be increased up to 6 carbons and its
molecular weight would still below 500.
Log P values, the partition coefficients, for all tylophorine analogs are below 5.
The partition coefficient is useful to estimate distribution of drugs within the body.
The number of H-bond donors is expressed as the sum of OH and NH. All our
tylophorine analogs contained less than 2. The number of H-acceptors is expressed as
the sum of N and O. All our tylophorine analogs are below 7. As result, all tylophorine
analogs would pass the Lipinski’s rule of five, which predicts a good oral absorption.
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Chapter seven: Experimental
Experimental procedure to scale-up DCB 3503
General Methods
All reactions were monitored using thin-layer chromatography (TLC).

Absorption

chromatography was carried out using Sorbent Technologies silica gel plates with a 200
mm thickness. All NMR spectroscopy was used the Varian 300 MHz NMR. Melting
points were determined on a Thomas-Hoover capillary melting point apparatus.
Positive-ion electrospray mass spectra were acquired on Accutof DART, MALDI, and
QUATRO-II quadrupole instrument.
Preparation of (E)-2,3-bis(3,4-dimethoxyphenyl)acrylic acid (3).
3,4-Dimethoxybenzaldehyde (1, 99+%, 15.0 g, 90.3 mmol) was stirred in Ac2O (55 mL)
and

TEA

(40

mL)

until

solution

was

completely

dissolved,

then

(3,4-

dimethoxyphenyl)acetic acid (2, 99%, 20.0 g, 102.0 mmol) was added. The solution was
heated slowly to 100 °C and left stirring overnight. The mixture was cooled to room
temperature, and water (50 mL) was added dropwise. An increase in temperature was
expected, so addition of water was stopped momentarily until temperature dropped to
room temperature. Then, a solution of K2CO3 (75 g) in water (250 mL) was added
dropwise. From experience, it is recommended to stop adding the K 2CO3 solution
momentarily if formation of sticky oily brown substance started to appear on the walls
and bottom of the beaker; then, continue adding K 2CO3 solution dropwise. If formation
of sticky substance was formed and stopped the stir bar, then the solution must be left
stand for 30-60 minutes at room temperature until it turned solid and stir bar was again
able to spin. The mixture was refluxed until all solids dissolved. Then, mixture was
cooled to room temperature and left spinning overnight. Mixture was separated with
Et2O (2 x 100 mL) and aqueous phase was collected (bottom). The aqueous layer was
acidified with 2 N HCl, which was added dropwise until pH 1 was reached. If a sticky
substance is formed, then the mixture must be left spinning for 30-60 minutes at room
temperature, at which time all should solidify; acidification was then continued. The
precipitation was recrystallized using MeOH to obtain 35.0 g of 3 (>90.0 % yield). mp:
208 °C. 1H NMR (CDCl3): δ 3.46 (3H, s), 3.80 (3H, s), 3.83 (3H, s), 3. 88 (3H, s), 6.54
(1H, s), 6.73 (1H, d), 6.78 (1H, s), 6.81 (1H, d), 6.84 (1H, d), 6.9 (1H, d), 7.83 (1H, d);
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13

C (NMR CDCl3): δ 55.42, 55.90, 55.92, 56.08, 111.83, 112.65, 112.85, 116.80,

116.82, 142.52. EIMS calcd for C19H20O6 m/z 344.13; found 345.126
Preparation of (E)-methyl 2,3-bis(3,4-dimethoxyphenyl)acrylate (4)
To a solution of compound 3 (13.0 g, 37.77 mmol) in MeOH (500 mL) stirred at 60 °C
was added dropwise H2SO4 (15 mL) and the solution was stirred overnight under reflux.
The mixture was concentrated by rotary evaporation at 35-40 °C ( do not heat above 50
°C lest a purple oily product form) and a liquid-solid residue formed. This crude product
was filtrated and washed quickly with cold MeOH. This solid was purified by column
chromatography (2:0.5 EtOAc:hexane), but most of the time it was not necessary. Yield:
13.05 g of 4 (>90%) mp: 125 °C. 1HNMR (CDCl3): δ 3.49 (3H, s), 3.80 (3H, s), 3.82 (3H,
s), 3.85 (3H, s), 3.90 (3H, s), 6.53 (1H, s), 6.73 (1H, m), 6.81 (1H, m), 6.84 (1H, m),
6.78 (1H, m), 6.90 (1H, m), 7.70 (1H, s); 13C NMR (CDCl3): δ 52.59, 55.42, 55.92, 56.00,
56.08, 110.49, 111.49, 112.49, 112. 98, 122.43, 125.43, 140.53. EIMS calcd for
C20H22O6 m/z 348.14; found 349.136
Preparation of methyl 2,3,6,7-tetramethoxyphenanthrene-9-carboxylate (5)
Method A: Using FeCl3
A solution of compound 4 (4.0 g, 11.17 mmol) in DCM (250 mL) was cooled to - 10°C.
Then a solution of anhydride FeCl3 (13 g, 80.83 mmol) in EtOAc (250 mL) was added
dropwise. The solution was stirred overnight, but the reaction was completed as soon
as FeCl3/EtOAc solution was added. The TLC was used to confirm completion of the
reaction (2:0.5 EtOAc:hexanes). The product’s spot must be bright blue with spray/heat
development with anisaldehyde-sulfuric acid.

†

The presence of a small brown spot on

the TLC plate (spots of product and starting material overlap), is indicative of the
presence of starting material. If this is the case, then the temperature of the solution
was lowered using an ice bath at -10 °C and a solution of FeCl3 anhydride in EtOAc was
added, the amount depending on the size of the brown spot. To quench the reaction,
water (250 mL) was added to the solution and mixture was allowed to stir for 3 hours or
until it turned dark yellow, if the solution had a dark green color, then more water was be
added. The solution was extracted with CHCl3 (3 x 50 mL) and dried with Na2SO4. The
mixture was filtered and solvent was evaporated at ≤ 35 °C, because the final
compound is heat sensitive. The crude product was purified by column chromatography
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(2:0.5 EtOAc:hexanes) to give 3.86 g 5 (>90%) mp. . 1HNMR (CDCl3): δ 4.01 (1H, s),
4.04 (1H, s), 4.07 (1H, s), 4.12 (1H, s), 4.14 (1H, s), 7.27 (1H, s), 7.77 (1H, s), 7.80 (1H,
s), 8.42 (1H, s), 8.65 (1H, s);

13

(CDCl3): δ 52.26, 52.5, 56.08, 56.09, 56.25, 56.26,

102.70, 102.87, 107.02, 109.50. EIMS calcd for C20H20O6 m/z 356.13; found 357.132
Method: VOF3
To a compound 4 (1.86, 5.19 mmol) was added DCM (18 mL), and mixture was stirred
at -10 °C. Then, a solution of VOF3 (2 g, 16.14 mmol), DCM (35 mL), EtOAc (17.5 mL),
TFA (1 mL), and TFAA (3 drops) was added dropwise with stirring. The solution was
stirred for 5 h at -10 °C. To quench the reaction, the mixture was poured onto ice and
extracted with CHCl3 (3 x 50 mL). The organic phase was dried with Na2SO4 and
filtered, and solvent was evaporated. The crude product was purified by column
chromatography (2:0.5 EtOAc:hexanes) to give 1.55 g (80%) of 5. TLC showed a bright
blue color under anisaldehyde TLC stain. In our experience, VOF3 is a toxic powder that
has to be open quickly inside a hood. The VOF3 solution stains glassware with a green
color that can be removed with 2 N HCl. This organic waste must be disposed of in a
separate container.
Preparation of (2,3,6,7-tetramethoxyphenylphenanthren-9-yl)methanol (6)
For this reduction, a three-neck round flask was outfitted to be maintained under an N 2
atmosphere. To a mixture of LiAlH4 (3.5 g, 92.22 mmol) in THF (280 mL) at - 10 °C was
added dropwise a solution of 5 (3.95 g, 11.09 mmol) in THF. Ice bath was removed, and
the mixture was stirred at room temperature overnight. The mixture was again cooled to
-10 °C and EtOAc (100 mL) was added dropwise, then Na2SO4·10H2O (around 10 g)
was added slowly until solution stopped bubbling and turned yellow. The mixture was
stirred overnight. Alternatively, 2 N HCl can be used instead of Na2SO4·10H2O to
quench the reaction, but lower yield generally resulted. The mixture was filtered, and the
solvent was evaporated by rotary evaporation. The crude product was purified by
column chromatography (2:0.5 EtOAc:hexanes) to give 3.18 g 6 (>90%) mp: 184 ° C.
1

HNMR (CDCl3): δ 4.03 (3H, s), 4.07 (3H, s), 4.12 (3H, s), 4.14 (3H, s), 5.14 (2H, s),

7.22 (1H, s), 7.56 (1H, s), 7.60 (1H, s), 7.78 (1H, s), 7.84 (1H, s);

13

C NMR (CDCl3): δ

56.00, 56.08, 56.10, 56.25, 65.04, 103.03, 103,37, 105.02, 108.67, 124.24. EIMS calcd
for C19H20O5 m/z 328.13; found 329.128.
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Preparation

of

(S)-methyl

5-oxo-1-((2,3,6,7-tetramethoxyphenanthren-9-

yl)methyl)pyrrolidine-2-carboxylate (7)
This reaction required three steps:
Step 1: A solution of compound 6 (3.4 g, 10.35 mmol) in freshly distilled CHCl3 (200 mL)
was cooled to -10 °C. (Using non-distilled CHCl3 increased side reactions). Then a
solution of PBr3 (4.8 mL, 17.93 mmol) in CHCl3 (5 mL) was added dropwise. Iced bath
was removed and solution was stirred at room temperature for 1.5 h. Then, the solution
was poured over ice and stirred until ice was completely melted. The product was
extracted with CHCl3 and dried over Na2SO4. The mixture was filtered, and solvent was
evaporated by rotary evaporation to obtain 6.1 as a yellow solid. Mp: 184 °C. 1HNMR
(CDCl3): δ4.02 (3H, s), 4.11 (3H, s), 4.12 (3H, s), 4.13 (3H, s), 4.99 (2H, s), 7.52 (1H, s),
7.67 (1H, s), 7.76 (1H, s), 7.18 (1H, s), 7.83 (1H, s);

13

C NMR (CDCl3): δ 56.01, 56.05,

56.07, 56.08, 33.85, 102.87, 103.53, 105.02, 108.50.
Step 2: The crude product 6.1 was added DMF (200 mL), glutamic acid dimethyl ester
27 (6 g, 28.35 mmol) and allowed to dissolve completely. Then K 2CO3 (10 g) was
added, and the mixture was stirred at 65 °C overnight. At higher or lower temperature,
side reactions were noted.
Step 3: The solvent was evaporated by high vacuum (~ 1 torr) rotary evaporation. The
residue was extracted with CHCl3, and the extract was washed with water and dried
with Na2SO4. The organic extract was filtered, and solvent was removed by rotary
evaporation. The crude product was dissolved in MeOH (80 mL) and AcOH (80 mL) and
stirred at 45 °C overnight. At higher or lower temperature, side reactions were formed.
The solvent was removed by rotary evaporation, then high-vacuum rotary evaporation
(~ 1 torr) to obtain a yellow solid. The crude product was purified by column
chromatography (2:0.5 EtOAc:hexanes) to give 3.4 g of 7 (>90 % yield). 1HNMR
(CDCl3): δ 2.08 (1H, m, J = 3.22 Hz), 2.12 (1H, m, J = 3.22 Hz), 2.24 (1H, m, J = 3.22),
2.48 (1H, m, J = 3.22 Hz), 3. 46 (3H, s), 3.84 (1H, dd, 3.23, 9.05 Hz), 4.03 (3H, s), 4.034
(3H, s), 4.12 (3H, s), 4.13 (3H, s) 4.4 (1H, m, J = 14.58 Hz), 5.49 (1H, m, 14.58 Hz),
7.19 (1H, s), 7.41 (1H, s), 7.61 (1H, s), 7.76 (1H, s), 7.81 (1H, s);

13

C NMR (CDCl3): δ

22.89, 24.88, 44.79, 52.43, 56.08, 56.74, 56.91, 58.73, 103.03, 103.19, 105.35, 108.34,
127.09. EIMS calcd for C25H27NO7 m/z 453.18; found 454.171
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Preparation of (S)-5-oxo-1-((2,3,6,7-tetramethoxyphenanthren-9-yl)pyrrolidine-2carboxylic acid (8)
Compound 7 (8.0 g, 17.65 mmol) was stirred in solution of 1,4-dioxane (100 mL), 2 N
KOH (200 mL), and MeOH (100 mL) for 1.5 h at room temperature. The solution was
acidified with 2 N HCl until pH 1, and extracted with CHCl3 and Et2O. Alternatively,
phosphoric acid can be used to quench the reaction, and a precipitate was formed. The
solvent was removed by rotary evaporation to give 8 7.4 g (80 % yield) mp 220-225 °C.
1

HNMR (CDCl3): δ 2.10 (2H, m), 2.40 (2H, m), 3.69 (1H, m), 4.30 (1H, m), 4. 00 (3H, m),

( 4.02 (3H, s), 4.10 (3H, m), 4.12 (3H, m), 5.64 (1H, m), 7.16 (1H, s), 7.44 (1H, s), 7.59
(1H, s), 7.74 (1H, s), 7.78 (1H, s);

13

C NMR (CDCl3): δ 21.90, 24.74, 51.10, 56.00,

56.08, 56. 41, 56.24, 67.36, 102. 87, 103.34, 104.26, 105.36, 108.51. EIMS calcd for
C24H25NO7 m/z 439.16; found 440.179.
Preparation

of

(S)-2,3,6,7-tetramethoxy-13,13a-dihydrodibenzo[f,h]pyrrolo[1,2-

b]isoquinoline-11,14(9H,12H)-dione (9)
Method A1: TFAA and BF3·Et2O
TFAA (4.0 mL) was added to a solution of compound 8 (0.58 g, 1.32 mmol) and 1,2dichloroethane (45 mL). It was noted that starting material did not dissolve in 1,2dichloroethane until TFAA was added. The solution was stirred at room temperature for
1 h. Then, BF3·Et2O (4 mL) was added and solution was stirred overnight at room
temperature. The majority of solvent was removed by rotary evaporation and DCM (50
mL) was added slowly. Then, a solution of saturated K 2CO3 in water was added
dropwise until release of CO2 stopped and solution turned yellow from a dark green
color. The solution was stirred overnight at room temperature (or for at least 5 hours).
Then, the mixture was filtrated, and the organic phase was extracted with CHCl3 and
water. The solvent was removed by rotary evaporation and purified by column
chromatography (2:1:0.3 CHCl3:EtOAc:MeOH) to give 9 0.4 g as a yellow powder. If
product became oily due to heating on the rotory evaporator, then EtOAc was added
until the product dissolved, and small amount of hexanes were added to precipitate
product. TLC typically showed the product as a yellow spot after it was ddeveloped in
anisaldehyde-H2SO4 TLC stain (65 %yield) mp. 1HNMR (CDCl3): δ 2.30 (1H, m), 2.40
(1H, m), 2.60 (1H, m), 2.62 (1H, m), 3.51 (3H, s), 3.91 (1H, m), 3.96 (3H. s), 4.05 (3H,
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m), 4.06 (3H, s), 4.35 (1H, s), 5.44 (1H, s), 7.09 (1H, s), 7.32 (1H, s), 7.53 (1H, s), 7.72
(1H, s);

13

C NMR (CDCl3): δ 30.07, 55.02, 55.07, 56.02, 56.06, 56.17, 56.32, 58.49,

61.17, 102.61, 102.99, 105.22, 108.14. EIMS calcd for C 24H23NO6 m/z 421.15; found
422.157.
Method A2: Oxalyl chloride and SnCl4
Compound 8 (0.5 g, 11.39 mmol) was dissolved in DCM (40 mL) and (CO)Cl 2 (0.4 mL,
3.15 mmol) was added dropwise, followed by the addition of a catalytic amount of DMF
(1-2 drops). Mixture was stirring for 1.5 h at room temperature, then, it was brought to
35 °C and SnCl4 (0.6 mL, 2.30 mmol) was added. The mixture was stirred for 4 h under
an N2 atmosphere at 35 °C. The reaction was cooled to room temperature and was
added cold 2 N HCl (3.5 mL). TLC showed a yellow spot as product after it was dipped
in anisaldehyde TLC reagent.

Preparation

of

(13aS,14S)-14-hydroxy-2,3,6,7-tetramethoxy-12,13,13a,14-

tetrahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-11(9H)-one (10)
A solution of compound 9 (3.76 g, 4.85 mmol) in dry THF (25 mL) under an N2
atmosphere was cooled to -10 °C. Then either K-selectride or L-selectride (1.0 M
solution in THF) (3.1 mL, 13.95 mmol) was added, and stirred for 5 h at – 35 °C. The
reaction was quenched by the addition of 2 N HCl (2 mL), and the product was
partitioned between CHCl3 and water. The organic solvent was removed by rotary
evaporation and the crude product was purified by column chromatography to give 10
(2.95 g, 75%). TLC (2:1:0.3 CHCl3:EtOAc:MeOH) generally showed an orange/red spot
for the product after the plate was developed with anisaldehyde-H2SO4 mp. 1HNMR
(CDCl3): δ 2.30 (1H, m), 2.36 (1H, m), 2.62 (1H, m), 2.63 (1H, m), 2.80 (1H, m), 3.94
(3H, s), 3.97 (1H, m), 4.09 (3H, s), 4.11 (3H, s), 4.12 (3H, s), 4.49 (1H, m), 5.19 (1H, m),
6. 98 (1H, s), 7.59 (1H, s), 7.75 (1H, s), 7.70 (1H, s);

13

C NMR (CDCl3): δ 30.20, 32.60,

40.02, 55.90, 56.06, 58.62, 64.69, 103.53, 103.60, 103.70, 104.46, 175.40. EIMS calcd
for C24H25NO6 m/z 423.17; found 424.179
Preparation

of

(13aS,

14S)-2,3,6,7-tetramethoxy-9,11,12,13,13a,14-

hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-13-ol (11)
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For this reduction, a three-neck round-bottom flask outfitted for an N2 atmosphere was
used. To a mixture of LiAlH4 (0.2 g, 7.11 mmol) in THF (60 mL) at -10 °C was added
dropwise a solution of 10 (0.27 g, 0.638 mmol) in THF. Ice bath was removed and
solution was stirred at room temperature overnight. The solution was brought back to 10°C, and EtOAc (50 mL) was added dropwise, then Na 2SO4·10H2O was added slowly
until the mixture stopped bubbling and turned yellow. (The mixture should not be left
spinning for more than 4 hours. The use of 2 N HCl to quench the reaction proved to
lower the yield.) The solution was filtered and solvent was removed by rotary
evaporation. The crude product was purified by column chromatography (2:1:0.5
CHCl3:EtOAc:MeOH) to give 11 0.15 g (60 % yield) mp. 1H NMR (CDCl3): δ 1.84 (1H,
m), 2.16 (1H, m), 2.20 (1H, m), 2.21 (1H, m), 2.82 (1H, m), 3.13 (1H, m), 3.77 (3H, s),
3.28 (1H, m), 4.10 (3H, s), 4.11 (3H, m) 4.16 (3H, m), 6.06 (1H, s), 7.37 (1H, s), 7.59
(1H, s), 7.89 (1H,s);

13

C NMR (CDCl3): δ 23.93, 24.02, 53.29, 55.71, 55.75, 55.92,

56.08, 64.93, 65.62, 102.2, 102.54, 102.7, 105.36. EIMS calcd for C 24H27NO5 m/z
409.19; found 410.197
Preparation of (S)-1,5-dimethoxy-1,5-dioxopentan-2-aminium chloride (BMPAC)
(27)
To a solution of L(+)-glutamic acid 26 (6 g, 40.80 mmol) in MeOH (300 mL) at -10 °C
was added dropwise SOCl2 (40 mL). Then, the solution was heated at 35 °C overnight.
Heating the solution at higher temperature produced a green or orange oil. The green
oil worked perfectly, but the orange oil was not the product expected. Solvent was
removed by rotary evaporation at 35 °C as yellow oil that hardened into white solid
under vacuum overnight.
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Experimental procedure for DCB 3503
Preparation of (E)-2,3-bis(3,4-dimethoxyphenyl)acrylic acid (3).
3,4-Dimethoxybenzaldehyde (1, 99+%, 15.0 g, 90.3 mmol) was stirred in Ac2O (55 mL)
and

TEA

(40

mL)

until

solution

was

completely

dissolved,

then

(3,4-

dimethoxyphenyl)acetic acid (2, 99%, 20.0 g, 102.0 mmol) was added. The solution was
heated slowly to 100 °C and left stirring overnight. The mixture was cooled to room
temperature, and water (50 mL) was added dropwise. Then, a solution of K 2CO3 (75 g)
in water (250 mL) was added dropwise. The mixture was refluxed until all solid
dissolved. Then, mixture was cooled to room temperature and left stirring overnight.
Mixture was separated with Et2O (2 x 100 mL) and water phase was collected (bottom).
The aqueous layer was acidified with 2 N HCl, which was added dropwise until pH 1
was reached. The precipitation was recrystallized using MeOH to obtain 3 (35.0 g,
>90.0 % yield). mp 218 °C (lit.1 215-216 °C); 1H NMR (CDCl3): δ 3.46 (3H, s), 3.80 (3H,
s), 3.83 (3H, s), 3. 88 (3H, s), 6.54 (1H, s), 6.73 (1H, d), 6.78 (1H, s), 6.81 (1H, d), 6.84
(1H, d), 6.9 (1H, d), 7.83 (1H, d);

13

C (NMR CDCl3): δ 55.42, 55.90, 55.92, 56.08,

111.83, 112.65, 112.85, 116.80, 116.82, 142.52. EIMS calcd for C19H20O6 m/z 344.126;
found 345.126.
Preparation of (E)-methyl 2,3-bis(3,4-dimethoxyphenyl)acrylate (4)
Compound 3 (13.0 g, 37.77 mmol) was added to MeOH (500 mL) and the solution was
stirred at 60 °C. Then, H2SO4 (15 mL) was added dropwise and solution was stirred
overnight. The solvent was removed by rotary evaporation at 40 °C and a precipitate
solid/liquid was formed. This product was filtrated and washed quickly with cold MeOH.
This solid was purified by column chromatography (2:0.5 EtOAc:hexane). To obtain 4
(13.05 g, >90%) mp 125 °C (lit.2 126 -127 °C). 1HNMR (CDCl3): δ 3.49 (3H, s), 3.80 (3H,
s), 3.82 (3H, s), 3.85 (3H, s), 3.90 (3H, s), 6.53 (1H, s), 6.73 (1H, m), 6.81 (1H, m), 6.84
(1H, m), 6.78 (1H, m), 6.90 (1H, m), 7.70 (1H, s);

13

C NMR (CDCl3): δ 52.59, 55.42,

55.92, 56.00, 56.08, 110.49, 111.49, 112.49, 112. 98, 122.43, 125.43, 140.53. EIMS
calcd for C20H22O6 m/z 358.142; found 359.136.
Preparation of methyl 2,3,6,7-tetramethoxyphenanthrene-9-carboxylate (5)
Method: FeCl3
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Compound 4 (4.0 g, 11.17 mmol) was added to DCM (250 mL) at -10 °C. Then a
solution of FeCl3 anhydride (13 g, 80.83 mmol) in EtOAc (250 mL) was added dropwise
and solution was stirred overnight. To quench the reaction, water (250 mL) was added
to the solution and allowed to stir for three hours. The solution was extracted with CHCl 3
(3 x 50 mL) and dried with Na2SO4. The solution was filtered and solvent was removed
by rotary evaporation. The crude product was purified by column chromatography (2:0.5
EtOAc:hexanes) to give 5 (3.86 g, >90%) mp: 202 °C (lit.3 203-205 °C). 1HNMR
(CDCl3): δ 4.01 (1H, s), 4.04 (1H, s), 4.07 (1H, s), 4.12 (1H, s), 4.14 (1H, s), 7.27 (1H,
s), 7.77 (1H, s), 7.80 (1H, s), 8.42 (1H, s), 8.65 (1H, s);

13

(CDCl3): δ 52.26, 52.5, 56.08,

56.09, 56.25, 56.26, 102.70, 102.87, 107.02, 109.50. EIMS calcd for C20H20O6 m/z
356.126; found 357.132.
Method: VOF3
Compound 4 (1.86, 5.19 mmol) was added DCM (18 mL) at stirred at -10 °C. Then, the
following solution was added dropwise: VOF3 (2 g, 16.14 mmol), DCM (35 mL), EtOAc
(17.5 mL), TFA (1 mL), and TFAA (3 drops). The solution was stirred for 5 h at -10 °C.
To quench the reaction, it was poured on ice and organic phase separated with CHCl 3
(3 x 50 mL). The solution was dried with Na2SO4, filtered, and solvent was removed by
rotary evaporation. The crude product was purified by column chromatography (2:0.5
EtOAc:hexanes) to give 5 (1.55 g, >90%) mp: 202 °C (lit.3 203-205 °C). VOF3 stains
glassware with a green color that can be removed with 2 N HCl.
Preparation of (2,3,6,7-tetramethoxyphenylphenanthren-9-yl)methanol (6)
To a mixture of LiAlH4 (3.5 g, 92.22 mmol) in THF (280 mL) at -10 °C was added
dropwise a solution of 5 (3.95 g, 11.09 mmol) in THF. Ice bath was removed and
solution was stirred at room temperature overnight. The solution was brought back to 10 °C and EtOAc (100 mL) was added dropwise, then Na2SO4·10H2O (around 10 g)
was added slowly. The solution was left stirred overnight. The solution was filtered and
solvent was removed by rotary evaporation. The crude product was purified by column
chromatography (2:0.5 EtOAc:hexanes) to give 6 (3.18 g, >90%) mp: 184 °C (lit.4 184185 °C). 1HNMR (CDCl3): δ 4.03 (3H, s), 4.07 (3H, s), 4.12 (3H, s), 4.14 (3H, s), 5.14
(2H, s), 7.22 (1H, s), 7.56 (1H, s), 7.60 (1H, s), 7.78 (1H, s), 7.84 (1H, s);

164

13

C NMR

(CDCl3): δ 56.00, 56.08, 56.10, 56.25, 65.04, 103.03, 103,37, 105.02, 108.67, 124.24.
EIMS calcd for C19H20O5 m/z 328.131; found 329.128.
Preparation

of

(S)-methyl

5-oxo-1-((2,3,6,7-tetramethoxyphenanthren-9-

yl)methyl)pyrrolidine-2-carboxylate (7)
This reaction required three steps:
Step 1: Compound 6 (3.4 g, 10.35 mmol) was added freshly distilled CHCl3 (200 mL) at
-10 °C. Using regular CHCl3 increased side reactions. Then a solution of PBr3 (4.8 mL,
17.93 mmol) in CHCl3 (5 mL) was added dropwise. Iced bath was removed and solution
was stirred at room temperature for 1.5 h. Then, the solution was poured over ice and
stirred until ice was completely melted. The organic phase was separated by extraction
using CHCl3 and dried over Na2SO4. The solution was filtered and solvent was removed
by rotary evaporation to obtain 6.1 as a yellow solid 9-(bromomethyl)-2,3,6,7tetramethoxyphenanthrene. 1HNMR (CDCl3): δ4.02 (3H, s), 4.11 (3H, s), 4.12 (3H, s),
4.13 (3H, s), 4.99 (2H, s), 7.52 (1H, s), 7.67 (1H, s), 7.76 (1H, s), 7.18 (1H, s), 7.83 (1H,
s);

13

C NMR (CDCl3): δ 56.01, 56.05, 56.07, 56.08, 33.85, 102.87, 103.53, 105.02,

108.50.
Step 2: The crude product 6.1 was added DMF (200 mL), glutamic acid dimethyl ester
27 (6 g, 28.35 mmol), and K2CO3 (10 g). The mixture was stirred at 65 °C overnight.
Step 3: The solvent was removed by high vacuum rotary evaporation. Extraction with
CHCl3 and water was used to obtain organic phase. Then, it was dried with Na 2SO4,
filtered, and solvent was removed by rotary evaporation. The crude product was
dissolved in MeOH (80 mL) and AcOH (80 mL) and stirred at 45 °C overnight. The
solution was removed by rotary evaporation and high vacuum rotary evaporation to
obtain a yellow solid. The crude product was purified by column chromatography (2:0.5
EtOAc:hexanes) to give 7 (3.4 g, >90 % yield) mp 215 °C (lit.5 210-215 °C). 1HNMR
(CDCl3): δ 2.08 (1H, m, J = 3.22 Hz), 2.12 (1H, m, J = 3.22 Hz), 2.24 (1H, m, J = 3.22),
2.48 (1H, m, J = 3.22 Hz), 3. 46 (3H, s), 3.84 (1H, dd, 3.23, 9.05 Hz), 4.03 (3H, s), 4.034
(3H, s), 4.12 (3H, s), 4.13 (3H, s) 4.4 (1H, m, J = 14.58 Hz), 5.49 (1H, m, 14.58 Hz),
7.19 (1H, s), 7.41 (1H, s), 7.61 (1H, s), 7.76 (1H, s), 7.81 (1H, s);

13

C NMR (CDCl3): δ

22.89, 24.88, 44.79, 52.43, 56.08, 56.74, 56.91, 58.73, 103.03, 103.19, 105.35, 108.34,
127.09. EIMS calcd for C25H27NO7 m/z 453.179; found 454.171.
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Preparation of (S)-5-oxo-1-((2,3,6,7-tetramethoxyphenanthren-9-yl)pyrrolidine-2carboxylic acid (8)
Compound 7 (8.0 g, 17.65 mmol) was stirred in solution of 1,4-dioxane (100 mL), 2 N
KOH (200 mL), and MeOH (100 mL) for 1.5 h at room temperature. The solution was
acidified with 2 N HCl until pH = 1, and extracted with CHCl3 and Et2O. The solvent was
removed by rotary evaporation to give 8 (7.4 g, 80 % yield) mp: 290-300 °C (lit.5 300302 °C). 1HNMR (CDCl3): δ 2.10 (2H, m), 2.40 (2H, m), 3.69 (1H, m), 4.30 (1H, m), 4. 00
(3H, m), ( 4.02 (3H, s), 4.10 (3H, m), 4.12 (3H, m), 5.64 (1H, m), 7.16 (1H, s), 7.44 (1H,
s), 7.59 (1H, s), 7.74 (1H, s), 7.78 (1H, s);

13

C NMR (CDCl3): δ 21.90, 24.74, 51.10,

56.00, 56.08, 56. 41, 56.24, 67.36, 102. 87, 103.34, 104.26, 105.36, 108.51. EIMS calcd
for C24H25NO7 m/z 439.163; found 440.179.

Preparation of (S)-2,3,6,7-tetramethoxy-13,13a dihydrodibenzo[f,h]pyrrolo[1,2b]isoquinoline-11,14(9H,12H)-dione (9)
Method TFAA and BF3·Et2O
TFAA (4.0 mL) was added to a solution of compound 8 (0.58 g, 1.32 mmol) and 1,2dichloroethane (45 mL). The solution was stirred at room temperature for 1 h. Then,
BF3·Et2O (4 mL) was added and solution was stirred overnight at room temperature.
Majority of solvent was removed by rotary evaporation and DCM (50 mL) was added
slowly. Then, a solution of saturated K2CO3 in water was added dropwise. The solution
was stirred overnight at room temperature. Then, it was filtrated and organic phase was
extracted with CHCl3 and water. The solvent was removed by rotary evaporation and
purified by column chromatography (2:1:0.3 CHCl3:EtOAc:MeOH) to give 9 (0.4 g, 65 %
yield) mp 225 °C (lit.5 228-230 °C). 1HNMR (CDCl3): δ 2.30 (1H, m), 2.40 (1H, m), 2.60
(1H, m), 2.62 (1H, m), 3.51 (3H, s), 3.91 (1H, m), 3.96 (3H. s), 4.05 (3H, m), 4.06 (3H,
s), 4.35 (1H, s), 5.44 (1H, s), 7.09 (1H, s), 7.32 (1H, s), 7.53 (1H, s), 7.72 (1H, s);

13

C

NMR (CDCl3): δ 30.07, 55.02, 55.07, 56.02, 56.06, 56.17, 56.32, 58.49, 61.17, 102.61,
102.99, 105.22, 108.14. EIMS calcd for C24H23NO6 m/z 421.153; found 422.157.
Method Oxalyl chloride and SnCl4
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Compound 8 (0.5 g, 11.39 mmol) was dissolved in DCM (40 mL) and (CO) 2Cl2 (0.4 mL,
3.15 mmol) was added dropwise with DMF (1-2 drops). Mixture was stirring for 1.5 h at
room temperature. Then, it was brought to 35 °C, to add SnCl 4 (0.6 mL, 2.30 mmol) for
4 h under N2 atmosphere. The reaction was cooled to room temperature and was added
cold 2 N HCl (3.5 mL). The solution was extracted withCHCl3 and H2O. The organic
phase was separated and dried with Na2SO4, filtered, and solvent removed by rotary
evaporation. Crude product was purified by column chromatography (2:1:0.3
CHCl3:EtOAc:MeOH) to give 9 0.35 g. (60-75 % yield) mp 225 °C.
Preparation of (13aS,14S)-14-hydroxy-2,3,6,7-tetramethoxy-12,13,13a,14tetrahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-11(9H)-one (10)
Compound 9 (3.76 g, 4.85 mmol) was added THF (25 mL) under N2 gas at -10 °C. Then
K-selectride (1.0 M solution in tetrahydrofuran) (3.1 mL, 13.95 mmol) was added and
stirred for 5 h. The solution was added 2 N HCl (2 mL). Then, organic phase was
extracted with CHCl3 and water. The solvent was removed by rotary evaporation and
purified by column chromatography. (2:1:0.3 CHCl3:EtOAc:MeOH) to give 10 (2.95 g, 75
% yield) mp 260 °C (lit.5 262 °C). 1HNMR (CDCl3): δ 2.30 (1H, m), 2.36 (1H, m), 2.62
(1H, m), 2.63 (1H, m), 2.80 (1H, m), 3.94 (3H, s), 3.97 (1H, m), 4.09 (3H, s), 4.11 (3H,
s), 4.12 (3H, s), 4.49 (1H, m), 5.19 (1H, m), 6. 98 (1H, s), 7.59 (1H, s), 7.75 (1H, s), 7.70
(1H, s);

13

C NMR (CDCl3): δ 30.20, 32.60, 40.02, 55.90, 56.06, 58.62, 64.69, 103.53,

103.60, 103.70, 104.46, 175.40.

EIMS calcd for C24H25NO6 m/z 423.168; found

424.179.
Preparation of (13aS, 14S)-2,3,6,7-tetramethoxy-9,11,12,13,13a,14hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-13-ol (11)
To a mixture of LiAlH4 (0.2 g, 7.11 mmol) in THF (60 mL) at -10 °C was added dropwise
a solution of 10 (0.27 g, 0.638 mmol) in THF. Ice bath was removed and solution was
stirred at room temperature overnight. The solution was brought back to -10°C and
EtOAc (50 mL) was added dropwise, then Na2SO4·10H2O was added. The use of 2 N
HCl to quench the reaction proved to lower the yield. The solution was filtered and
solvent was removed by rotary evaporation. The crude product was purified by column
chromatography (2:1:0.5 CHCl3:EtOAc:MeOH) to give 11 0.15 g (60 % yield) mp 268 °C
(lit.5 270 °C). 1H NMR (CDCl3): δ 1.84 (1H, m), 2.16 (1H, m), 2.20 (1H, m), 2.21 (1H, m),
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2.82 (1H, m), 3.13 (1H, m), 3.77 (3H, s), 3.28 (1H, m), 4.10 (3H, s), 4.11 (3H, m) 4.16
(3H, m), 4.81 (1H,s), 6.06 (1H, s), 7.37 (1H, s), 7.59 (1H, s), 7.89 (1H,s);

13

C NMR

(CDCl3): δ 23.93, 24.02, 53.29, 55.71, 55.75, 55.92, 56.08, 64.93, 65.62, 102.2, 102.54,
102.7, 105.36. EIMS calcd for C24H27NO5 m/z 409.189; found 410.189.
Preparation of (S)-1,5-dimethoxy-1,5-dioxopentan-2-aminium chloride (BMPAC)
(27)
To a solution of L(+)-glutamic acid 26 (6 g, 40.80 mmol) in MeOH (300 mL) at -10 °C
was added dropwise SOCl2 (40 mL). Then, the solution was heated at 35 °C overnight.
Solvent was removed by rotary evaporation at 35 °C as yellow oil. A white precipitate
was formed in vacuum overnight.

Preparation of anisaldehyde TLC stain
This clear stain was prepared by dissolving p-anisaldehyde (9.2 mL) in EtOH (338 mL)
containing conc. H2SO4 (12.5 mL) and acetic acid (3.75 mL). The plate was developed
by heating on a hot plate/drier.
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Experimental procedure for DCB 3507
Synthesis of (E)-3-(3,4-dimethoxyphenyl)-2-phenylacrylic acid (13)
3,4-dimethoxybenzaldehyde (1, 99+%, 15.0 g, 90.3 mmol) was stirred in Ac2O (55 mL)
and TEA (40 mL), then 2-phenylacetic acid 12 (20.0 g, 147.0 mmol) was added. The
solution was heated to 100 °C and left stirring overnight. The mixture was cooled to
room temperature and water (50 mL) was added dropwise. Then, a solution of K2CO3
(75 g) in water (250 mL) was added dropwise. The solution was refluxed until all solid
dissolved and left spinning overnight at room temperature. The mixture was separated
with Et2O (2 x 100 mL) and water phase was collected. The aqueous layer was acidified
with 2 N HCl until pH = 1 was reached. The precipitation was recrystallized using MeOH
to obtain 13 (35.0 g, >90.0 % yield). mp 220 °C.1HNMR (CDCl3): δ 3.36 (3H, s), 3.84
(3H, s), 6.41 (1H, s), 6.74 (1H, d), 6.88 (1H, d), 7.29 (1H, m), 7.34 (1H, m), 7.39 (1H,
m), 7.42 (1H, d), 7.81 (1H, s); 13C NMR (CDCl3): δ 55.25, 55.91, 110.83, 112.32, 126.26,
128.25, 129.08, 130.24, 130.26, 142.68, 172.89. EIMS calcd for C 17H16O4 m/z 284.105;
found 285.111.
Synthesis of (E)-methyl 3-(3,4-dimethoxyphenyl)-2-phenylacrylate (14)
Compound 13 (13.0 g, 45.76 mmol) was added MeOH (500 mL) and the solution was
stirred at 60 °C. Then, H2SO4 (15 mL) was added dropwise, and solution was stirred
overnight. The solvent was removed by rotary evaporation at 35 °C and a precipitate
formed. This product was washed with cold MeOH. The precipitate was purified by
column chromatography (2:0.5 EtOAc:hexane). To obtain 14 (13.05 g, >90%) mp 160
°C. 1HNMR (CDCl3): δ 3.50 (3H, s), 3.82 (3H, s), 3.90 (3H, s), 5.74 (1H, d), 6.48 (1H,
d), 6.77 (1H, d), 6.79 (1H, t), 6.83 (1H, t), 6.91 (1H, t), 6.93 (1H, d), 7.26 (1H, s), 7.75
(1H, s);

13

C NMR (CDCl3): δ 52.30, 55.34, 55.92, 111.48, 112.04, 114. 06, 122.21,

126.97, 140.56, 145.84, 148.56, 149.27. EIMS calcd for C18H18O4 m/z 298.121; found
299.123.
Synthesis of methyl 2,3-dimethoxyphenanthrene-9-carboxylate (15)
Method FeCl3 and SiO2
Compound 14 (3.2 g, 10.73 mmol) was added DCM (320 mL) at room temperature.
Then, a fresh mixture of FeCl3:SiO2 (11 g: 11 g) was added to the solution to be ran for
two days at room temperature. The solution was filtered and mixture was separated with
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CHCl3. The solvent was removed by rotary evaporation at 35 °C. SiO 2 was dried
overnight to obtain higher yield. This product was purified by column chromatography
(2:0.5 EtOAc:hexane). To obtain 15 as a yellow powder (1.43 g, >90%) mp 128 °C.
1

HNMR (CDCl3): δ 4.03 (3H, s), 4.05 (3H, s), 4.14 (3H, s), 7.25 (1H, d), 7.62 (1H, t),

7.64 (1H, t), 7.98 (1, s), 8.44 (1H, s), 8.55 (1H, s), 8.99 (1H, d); ); 13C NMR (CDCl3): δ
52.13, 55.98, 56.05, 103.04, 109.21, 126.44, 126. 54,126. 69, 130.03, 168.13. EIMS
calcd for C18H16O4 m/z 296.105; found 297.086.
Method VOF3 and TFA
Compound 14 (2.5, 8.38 mmol) was added DCM (35 mL) and stirred at -10 °C. Then,
the following solution was added dropwise: VOF3 (2.5 g, 20.17 mmol), DCM (58 mL),
EtOAc (35 mL), TFA (2 mL), and TFAA (3 drops). The solution was stirred for 5 h at -10
°C. To quench the reaction, it was poured on ice and organic phase separated with
CHCl3 (3 x 50 mL). The solution was dried with Na2SO4, filtered, and solvent was
removed by rotary evaporation. The crude product was purified by column
chromatography (2:0.5 EtOAc:hexanes) to obtain 15 as a yellow powder (3.07 g, >
90%) mp 128 °C. EIMS calcd for C18H16O4 m/z 296.105; found 297.106.
Synthesis of (2,3-dimethoxyphenanthren-9-yl)methanol (16)
To a mixture of LiAlH4 (0.5 g, 13.15 mmol) in THF (48 mL) at -10 °C was added
dropwise a solution of 15 (1.2 g, 4.05 mmol) in THF. Ice bath was removed and solution
was stirred at room temperature overnight. The solution was brought back to -10 °C and
was added EtOAc (50 mL) dropwise, then Na2SO4·10H2O was added until solution
turned yellow. Alternatively, 2 N HCl can be used to quench the reaction, but
Na2SO4·10H2O gave a better yield. The solution was filtered and solvent was removed
by rotary evaporation. The crude product was purified by column chromatography (2:0.5
EtOAc:hexanes) to 16 as a yellow power (1.14 g, >90%) mp 150 °C. 1HNMR (CDCl3): δ
4.05 (3H, s), 4.13 (3H, s), 5.19 (2H, s), 5.60 (1H, s), 7.71 (1H, s), 7.23 (1H, s), 7.60 (1H,
t), 7.67 (1H, t), 8.00 (1H, s), 8.19 (1H, d), 8.60 (1H, d);

13

C NMR (CDCl3): δ 64.19,

103.53, 108.67, 122.94, 124.77, 125.27, 126.00, 126.59. EIMS calcd for C 18H16O4 m/z
268.110; found 269.109.
Synthesis of (S)-methyl 1-((2,3-dimethoxyphenanthren-9-yl)methyl)-5oxopurrolidine-2-carboxylate (17)
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Step 1: Compound 16 (1.14 g, 4.25 mmol) was added freshly distilled CHCl3 (98 mL) at
-10°C. Then a solution of PBr3 (1 mL, 3.65 mmol) in CHCl3 (20 mL) was added
dropwise. Iced bath was removed and solution was stirred at room temperature for 1.5
h. Then, it was poured over ice and stirred until ice was completely melted. The organic
phase was separated by extraction using CHCl3 and dried over Na2SO4. The solution
was filtered and solvent was removed by rotary evaporation.
Step 2: The crude product was added DMF (118 mL), glutamic acid dimethyl ester 27
(3.2 g, mmol), and allowed to dissolve completely. Then K 2CO3 (3.2 g) was added and
the mixture was stirred at 65 °C overnight.
Step 3: The solvent was removed by high vacuum rotary evaporation. Extraction with
CHCl3 and water was used to obtain organic phase. Then, it was dried with Na 2SO4,
filtered, and solvent was removed by rotary evaporation. The crude product was
dissolved in MeOH (63 mL) and AcOH (63 mL) and stirred at 45 °C overnight. The
solution was removed by rotary evaporation and high vacuum rotary evaporation. The
crude product was purified by column chromatography (2:1 EtOAc:hexanes) to give 17
as a yellow powder (1.06 g, >90 % yield). mp 148 °C. 1HNMR (CDCl3): δ 1.94 (1H, m, J
= 9.4 Hz), 2.07 (1H, m, J = 9.4 Hz), 2.41 (1H, m, J = 9.4 Hz), 3.76 (1H, dd, J = 2.98,
9.15 Hz), 4.08 (3H, s), 3.99 (3H, s), 3.47 (3H, s), 4.42 (1H, d, J = 14.63 Mz), 5.47 (1H,
d, J = 14.63 Hz), 7.09 (1H, s), 7.44 (1H, t, J = 7.9 Hz), 7.50 (1H, s), 7.56 (1H, t, J = 7.9
Hz), 7.89 (1H, s), 8.01 (1H, t, J = 7.9 Hz), 8.5 (1H, d, J = 7.9 Hz);

13

C NMR (CDCl3): δ

22.81, 30.03, 44.47, 52.26, 52.26, 56.08, 58.74, 103.36, 108.34, 122.94, 124.93,
126.42, 126.59, 128.58, 171.6, 172.7. EIMS calcd for C 23H23NO5 m/z 393.158; found
394.164

Synthesis

of

(S)-1-((2,

3-dimethoxyphenanthren-9-yl)-5-oxopyrrolidine-2-

carboxylic acid (18)
Compound 17 (1.06 g, 2.69 mmol) was stirred in solution of 1,4-dioxane (40 mL), 2 N
KOH (25 mL), and MeOH (40 mL) for 2 h at room temperature. The solution was
acidified with 2 N HCl until pH 1, and extracted with CHCl3 and Et2O. The solvent was
removed by rotary evaporation to give 18 (1.04 g, >90 %) mp 160 °C. 1HNMR (CDCl3) δ
1.90 (1H, m), 2.0 (1H, m), 2.41 (1H, m), 2.60 (1H, m), 3.8 (1H, m), 4.42 (1H, m), 5.74
171

(1H, m), 6.93 (1H, s), 7.57 (1H, s), 7.63 (1H, t), 7.67 (1H, t), 8.01 (1H, s), 8.10 (1H, d),
8.57 (1H, d);

13

C NMR (CDCl3): δ 21.05, 30.01, 41.3, 59.6, 110.2, 119.0, 121.5, 121.8,

122.4, 122.6, 123.4, 176.4, 178.4. EIMS calcd for C22H21NO5 m/z 379.142; found
380.150.
Alternative method to quench reaction 18: DOWEX 50 (H+) resin
To prepare resin: (use wet resin)
Dovex 50 was washed with diluted 4:1 HCl:water. Then, it was washed with DI water
until neutral. The solution RCOO- K+ was added until pH is 1-2, and resin was filtered
off. Product was extracted and dried in rotary evaporation to obtain white powder.
Synthesis

of

(S)-2,3-dimethoxy-13,13a-dihydrodibenzo[f,h]pyrrolo[1,2-

b]isoquinoline-11,14(9H, 12H)-dione (19)
Method TFAA and BF3·Et2O
TFAA (1.5 mL) was added to a solution of compound 18 (1.32 g, 3.48 mmol) and 1,2dichloroethane (30 mL). The solution was stirred at room temperature for 1 h. Then,
BF3·Et2O (1.5 mL) was added and solution was stirred overnight at room temperature.
Majority of solvent was removed by rotary evaporation and DCM (15 mL) was added
slowly. Then, a solution of saturated K2CO3 in water was added dropwise until release
of CO2 stopped and solution turned yellow from a dark green color. Solution was stirred
overnight at room temperature or at least five hours. Then it was filtrated and organic
phase extracted with CHCl3 and water. Solvent was removed by rotary evaporation and
purified by column chromatography (2:1:0.3 CHCl3:EtOAc:MeOH) to give 19 (0.93 g, 5070 %) mp 155 °C. 1HNMR (CDCl3) δ 2.57 (1H, m), 2.59 (1H, m), 2.60 (1H, m), 2.62 (1H,
m), 4.09 (3H, s), 4.12 (3H, s), 4.43 (1H, m), 4.79 (1H, m), 5.86 (1H, m), 7.64 (1H, t),
7.78 (1H, t), 7.97 (1H, s), 8.12 (1H, d), 9.03 (1H, s);

13

C NMR (CDCl3): δ 20.74, 30.59,

40.82, 61.4, 55.92, 56.08, 103.0, 107.9, 124.8, 125.0, 125.1,128.6. EIMS calculated for
C22H21NO4 m/z 361.131, found 362.138
Method Oxalyl chloride and SnCl4
Compound 18 (0.5 g, 1.32 mmol) was dissolved in DCM (40 mL) and (CO) 2Cl2 (0.4 mL,
3.18 mmol) was added dropwise with DMF (1-2 drops). Mixture was stirring for 1.5 h at
room temperature. Then, it was brought to 35 °C, to add SnCl 4 (0.6 mL, 2.31 mmol) for
4 h under N2 atmosphere. The reaction was cooled to room temperature and was added
172

cold 2 N HCl (mL). The solution was extracted with CHCl3 and H2O. The organic phase
was separated and dried with Na2SO4, filtered, and solvent removed by rotary
evaporation. Crude product was purified by column chromatography (2:1:0.3
CHCl3:EtOAc:MeOH) to give (19 g, 60-75 % yield) mp 155 °C.
Synthesis of (13aS, 14S)-14-hydroxy-2,3-dimethoxy-12.13,13a,14tetrahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-11(9H)-one (20)
Compound 19 (0.9 g, 2.49 mmol) was added THF (26 mL) under N2 gas at -10 °C. Then
K-selectride (1.0 M solution in tetrahydrofuran) (4.5 mL, mmol) was added and stirred
for 5 h. Solution was added 2 N HCl (0.7 mL). Then organic phase was extracted with
CHCl3 and water. Solvent was removed by rotary evaporation and purified by column
chromatography (2:1:0.3 CHCl3:EtOAc:MeOH) to give 20 (0.47 g, >90 %) mp 118 °C.
1

H NMR (CDCl3): δ 2.30 (1H, m), 2.32 (1H,m), 2.49 (1H, J = 4,38 Hz), 2.58 (1H, m), 3.96

(1H, m), 4.07 (3H, s), 4.08 (3H, s), 4.52 (1H, d, J = 17.49 Hz), 5.17 (1H, m), 5.42 (1H, d,
J = 17.62 Hz), 7.52 (1H, t), 7.53 (1H, t), 7.60 (1H, s), 7.84 (1H, d), 7.93 (1H, s), 8.50
(1H, d, J = 8.34 Hz);

13

C NMR (CDCl3): δ 30.94, 31.03, 40.03, 41.01, 56.23, 56.19,

58.47, 58.47, 65.95, 103.77, 104.47, 122.82, 123.59, 126.62,128.14. EIMS calculated
for C22H21NO4 m/z 363.147, found 364.136
Synthesis of (13aS, 14S)-2,3-dimethoxy-9,11,12,13a,14hexahydrodibenzo[f,g]pyrrolo[1,2-b]isoquinolin-14-ol (21)
To a mixture of LiAlH4 (1.2 g, mmol) in THF (33 mL) at -10 °C was added dropwise a
solution of 20 (0.47 g, 1.29 mmol) in THF. Ice bath was removed and solution was
stirred at room temperature overnight. The solution was brought back to -10 °C and
EtOAc (33 mL) was added dropwise, then Na2SO4·10H2O was added until solution
turned yellow, but it should not be left spinning for more than four hours . The solution
was filtered and solvent was removed by rotary evaporation. The crude product was
purified by column chromatography (2:1:0.5 CHCl3:EtOAc:MeOH) to give 21 (0.40 g, 6070 %) mp 168 °C. 1H NMR (CDCl3): δ 1.75 (1H, m), 1.79 (1H, m), 1.90 (1H, m), 2.03
(1H, m), 2.13 (1H, m, J = 4.42 Hz), 2.30 (1H, m), 2.93 (1H, d, J = 15.42 Mz), 2.95 (1H,
m), 3.2 (1H, d, J = 15.42 Mz), 4.04 (3H, s), 4.1 (3H, s), 4.75 (1H, m, 1.78 Mz), 6.80 (1H,
d, J = 8.12 Mz), 7.05 (1H, m, J = 7.29 Mz), 7.39 (1H, m, J = 7.34 Mz), 7.81 (1H, s), 7.87
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(1H, s), 8.29 (1H, d, J = 8.32 Mz); ); 13C NMR (CDCl3): 21.4, 24.06, 53.43, 55.42, 55.92,
56.25, 64.87, 103.36, 105.36, 122.28, 122.61, 125.59, 126.26. EIMS calculated for
C22H23NO3 m/z 349.17, found 350.191.
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Experimental procedure for DCB 3508
Synthesis of (S)-2-(methoxycarbonyl)pyrrolidinium chloride (23)
To a solution of L(-)-proline 22 (4.6 g, 39.98 mmol) in MeOH (40 mL) at -30°C was
added SOCl2 (4 mL). The solution was heated at reflux for 1 h. Solvent was removed by
rotary evaporation as a yellow oil and precipitate was formed in vacuum overnight.
Synthesis of (S)-methyl 1-(2,3,6,7-tetramethoxyphenanthren-9 yl)
methyl)pyrrolidine-2-carboxylate (24)
To a solution of 6.1 (0.3 g, 0.77 mmol) and acetone (30 mL) was added 23 (0.2 g, 1.21
mmol) and NaI (1g). The solution was refluxed for 48 h. Solvent was removed by rotary
evaporation to obtain an oily compound, which was precipitated by adding EtOAc and
hexanes (70:30 v/v) to give 24 (0.4 g, > 90%) mp 197 °C. 1H NMR (CDCl3): δ 1.18 (1H,
m), 1.89 (1H, m), 1.68 (1H, m), 2.12 (1H, m), 2.28 (1H, m), 2.78 (1H, m), 3.19 (1H, m),
3.53 (1H, m), 3.61 (1H, m), 4.03 (3H, s), 4.04 (3H, s), 4.05 (3H, m), 4.48 (3H, s), 4.49
(1H, s), 7.08 (1H, s), 7.37 (1H, s), 7.68 (1H, s), 7.70 (1H, s), 8.09 (1H, s);

13

C NMR

(CDCl3): 22.89, 29.53, 51.76, 55.92, 56.18, 56.20, 56.24, 58.74, 102.86, 102.70,
106.68, 125.43. EIMS: calcd for C25H29NO6 m/z 439.199; found 440.205.
Synthesis of (S)-1(-((2,3,6,7-tetramethoxyphenanthren-9-yl)methylpyrrolidin-2yl)methanol (25)
To a mixture of LiAlH4 (1.7g, 44. 79 mmol) in THF (100 mL) at -10 °C was added
dropwise a solution of 24 (0.94g, 2.14 mmol) in THF. Ice bath was removed and
solution was stirred at room temperature overnight. The solution was brought back to 10 °C and was added EtOAc (50 mL) dropwise, then Na 2SO4·10H2O was added until
solution turned yellow. The solution was filtered and solvent was removed by rotary
evaporation. The crude product was purified by column chromatography (2:1:0.5
CHCl3:EtOAc:MeOH) to give 25 (0.9 g, >90 %) mp 201 °C. 1H NMR (CDCl3): δ 1.73
(1H,m), 1.86 (1H,m),1.89 (1H,m), 2.03 (1H,m), 2.43 (1H,m), 2.89 (1H,m), 2.92 (1H,m),
3.49 (1H, d), 3.75 (1H, d), 3.77 (1H,m), 4.04 (3H, s), 4.08 (3H, s), 4.12 (3H, s), 4.13 (3H,
s), 4.49 (1H, d), 7.21 (1H, s), 7.54 (1H, s), 7.61 (1H, s), 7.79 (1H, s), 7.84 (1H, s); 13C
NMR (CDCl3): 50.77, 54.59, 55.92, 56.08, 56.22, 59.23, 62.55, 65.21, 103.3, 104.86,
108.34, 125.76. EIMS calculated for C24H29NO5 m/z 411.205; found 412.209.
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Experimental procedure for DCB 3506
Synthesis

of

(E)-3-(4-acetoxy-3-methoxyphenyl)-2-(3,4-dimethoxy)acrylic

acid

(27).
3-hydroxy-4-methoxybenzaldehyde (26, 99+%, 15.0 g, 98.6 mmol) was stirred in Ac2O
(55 mL) and TEA (40 mL) until solution was completely dissolved, then (3,4dimethoxyphenyl)acetic acid (2, 99%, 20.0 g, 102.0 mmol) was added. The solution was
heated slowly to 100 °C and left stirring overnight. The mixture was cooled to room
temperature, and water (50 mL) was added dropwise. Then, a solution of K 2CO3 (75 g)
in water (250 mL) was added dropwise. The mixture was refluxed until all solid
dissolved. Then, mixture was cooled to room temperature and left stirring overnight.
Mixture was separated with Et2O (2 x 100 mL) and water phase was collected (bottom).
The aqueous layer was acidified with 2 N HCl, which was added dropwise until pH 1
was reached. The precipitation was recrystallized using MeOH to obtain 27 (39.0 g,
>90.0 % yield). mp 172.9 °C (lit.6 170.9-176.2 °C); 1H NMR (CDCl3): δ 2.28 (3H, s),
3.46 (3H, s), 3.82 (3H, s), 3.89 (3H, s), 6.66 (1H, s), 6.77 (1H, m), 6.84 (1H, m), 6.89
(1H, m), 6.90 (1H, m), 6.92 (1H, m), 7.86 (1H, s);

13

C (NMR CDCl3): δ 55.42, 55.90,

55.92, 56.08, 111.52, 112.75, 113.93, 114.20, 119.60, 142.63, 195.91. EIMS calcd for
C20H20O7 m/z 372.121; found 373.126.
Synthesis of (E)-methyl 2-(3,4-dimethoxyphenyl)-3-(4-hydroxy-3-methoxy)acrylate
(28)
Compound 27 (13.0 g, 34.93 mmol) was added to MeOH (500 mL) and the solution was
stirred at 60 °C. Then, H2SO4 (15 mL) was added dropwise and solution was stirred
overnight. The solvent was removed by rotary evaporation at 40 °C and a precipitate
solid/liquid was formed. This product was filtrated and washed quickly with cold MeOH.
This solid was purified by column chromatography (2:0.5 EtOAc:hexane). To obtain 28
(12.50 g, >90%) mp 126 °C (lit.6 121.7 -123.5 °C). 1HNMR (CDCl3): δ 3.50 (3H,s), 3.79
(3H, s), 3.82 (3H, s), 3.90 (3H, s), 6.66(1H, s), 6.76 (1H, m), 6.77 (1H, s), 6.78 (1H, m),
6.91 (1H, m), 7.75 (1H, s), 7.87 (1H, m);

13

C NMR (CDCl3): δ 55.29, 55.32, 55.90,

111.47, 112.89, 114.09, 122.19, 126.96, 140.55, 142.63, 195.91. EIMS calcd for
C19H20O6 m/z 344.126; found 345.122.
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Synthesis of (E)-methyl 3-(4-acetoxy-3-methoxyphenyl)-2-(3,4dimethoxyyphenyl)acrylate (29)
Compound 28 (2.5 g, 7.26 mmol) was added TEA (20 mL) and Ac 2O (15 mL) and
solution was left stirring for 1 h at room temperature. The product 29 precipitated as
yellow powder. In case product would not precipitate, the reagents (TEA and Ac 2O)
were evaporated using high vacuum, and product was filtrated to give 29 (2.8 g, >90%)
mp: 108 °C (lit.6 110.5-114.8 °C). 1H NMR(CDCl3): δ 2.27 (3H, s), 3.46 (1H, s), 3.80 (3H,
s), 3.81 (3H, s), 3.89 (3H, s), 6.23 (1H, m), 6.62 (1H, m), 6.89 (1H, m), 6.88 (1H, s),
6.90 (1H, s), 7.76 (1H, s);

13

C(CHCl3): δ 52.34, 55.34, 55.90, 55.91, 110.12, 111.43,

113.76, 122.11, 122.16, 124.17, 140.27, 170.64. EIMS calcd for C21H22O7 m/z 386.136;
found 387.132.
Synthesis of methyl 3-acetoxy-2,6,7-trimethoxyphenanthrene-9-carboxylate (30)
Compound 28 (1.86, 48.17 mmol) was added DCM (18 mL) at stirred at -10 °C. Then,
the following solution was added dropwise: VOF3 (2 g, 16.14 mmol), DCM (35 mL),
EtOAc (17.5 mL), TFA (1 mL), and TFAA (3 drops). The solution was stirred for 5 h at 10 °C. To quench the reaction, it was poured on ice and organic phase separated with
CHCl3 (3 x 50 mL). The solution was dried with Na2SO4, filtered, and solvent was
removed by rotary evaporation. The crude product was purified by column
chromatography (2:0.5 EtOAc:hexanes) to give 30 (1.55 g, >90%) mp: 122 °C (lit.6
121.7-123.5 °C). VOF3 stains glassware with a green color that can be removed with 2
N HCl. 1H NMR (CDCl3): δ 2.40 (3H, s), 3.96 (3H, s), 4.05 (3H, s), 4.08 (3H, s), 4.09
(3H, s), 7.34 (1H, s), 7.76 (1H, s), 8.12 (1H, s), 8.40 (1H, s);

13

C(CDCl3): δ 20.76, 52.10,

52,18, 55.13, 55.98, 102.71, 106.70, 110.26, 116.11, 129.90. EIMS calcd for C21H20O7
m/z 384.121; found 385.132.
Synthesis of 9-(hydroxymethyl)-2,6,7-trimethoxyphenanthren-3-ol (31)
To a mixture of LiAlH4 (3.5 g, 92.22 mmol) in THF (280 mL) at -10 °C was added
dropwise a solution of 30 (3.95 g, 10.28 mmol) in THF. Ice bath was removed and
solution was stirred at room temperature overnight. The solution was brought back to 10 °C and EtOAc (100 mL) was added dropwise, then Na2SO4·10H2O (around 10 g)
was added slowly. The solution was left stirred overnight. The solution was filtered and
solvent was removed by rotary evaporation. The crude product was purified by column
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chromatography (2:0.5 EtOAc:hexanes) to give 31 (3.20 g, >90%) mp: 189 °C (lit.6
189.4-192.1 °C). 1HNMR (CDCl3): δ 4.05 (3H, s), 4.08 (3H, m), 4.09 (3H, s), 5.95 (1H,
s), 7.11 (1H, s), 7.19 (1H, s), 7.52 (1H, s), 7.56 (1H, s), 7.84 (1H, s), 7.96 (1H, s);

13

C

NMR (CDCl3): δ 56.00, 56.10, 56.12, 63.4, 104.00, 104.70, 104.80, 109.00. EIMS calcd
for C18H28O5 m/z 314.115; found 315.118.
Synthesis

of

1-((3-hydroxy-2,6,7-trimethoxyphenanthren-9-yl)methyl)-5-

oxopyrrolidine-2-carboxylate (32)
This reaction required three steps:
Step 1: Compound 31 (3.5 g, 11.14 mmol) was added freshly distilled CHCl3 (200 mL)
at -10 °C. Using regular CHCl3 increased side reactions. Then a solution of PBr3 (4.8
mL, 17.93 mmol) in CHCl3 (5 mL) was added dropwise. Iced bath was removed and
solution was stirred at room temperature for 1.5 h. Then, the solution was poured over
ice and stirred until ice was completely melted. The organic phase was separated by
extraction using CHCl3 and dried over Na2SO4. The solution was filtered and solvent
was removed by rotary evaporation to obtain the brominated intermediate as a yellow
solid
Step 2: The crude product intermediate was added DMF (200 mL), glutamic acid
dimethyl ester (6 g, 28.35 mmol), and K2CO3 (10 g). The mixture was stirred at 65 °C
overnight.
Step 3: The solvent was removed by high vacuum rotary evaporation. Extraction with
CHCl3 and water was used to obtain organic phase. Then, it was dried with Na 2SO4,
filtered, and solvent was removed by rotary evaporation. The crude product was
dissolved in MeOH (80 mL) and AcOH (80 mL) and stirred at 45 °C overnight. The
solution was removed by rotary evaporation and high vacuum rotary evaporation to
obtain a yellow solid. The crude product was purified by column chromatography (2:0.5
EtOAc:hexanes) to give 32 (3.8 g, >90 % yield) mp 215 °C (lit.6 210-215 °C). 1HNMR
(CDCl3): δ 2.34 (1H, s), 2.62 (2H, m), 3.57 (3H, s), 3.82 (1H, m), 4.03 (3H, s), 4.05 (3H,
m), 4.08 (3H, m), 4.43 (1H, d), 5.52 (1H, d), 7.16 (1H, s), 7.38 (1H, s), 7.59 (1H, s), 7.83
(1H, s), 7.96 (1H, s);

13

C NMR (CDCl3): 22.90, 29.70, 47.60, 56.00, 56.10, 56.22, 66.1,

104.30, 108.00, 108.30, 109.00, 171.12. EIMS calcd for C24H25NO7 m/z 439.163; found
440.166.
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Synthesis of 1-((3-hydroxy-2,6,7-trimethoxyphenanthren-9-yl)methyl)-5oxopyrrolidine-2-carboxylic acid (33)
Compound 32 (8.0 g, 18.22 mmol) was stirred in solution of 1,4-dioxane (100 mL), 2 N
KOH (200 mL), and MeOH (100 mL) for 1.5 h at room temperature. The solution was
acidified with 2 N HCl until pH = 1, and extracted with CHCl3 and Et2O. The solvent was
removed by rotary evaporation to give 33 (7.8 g, 80 % yield) mp: 318 °C (lit.6 320 °C).
1

HNMR (CDCl3): δ 2.26 (2H, m), 2.47 (2H ,m), 3.59 (1H, d), 3.85 (3H, s), 3.88 (3H, s),

3.91 (3H, s), 4.19 (1H, d), 5.51 1H, d), 7.16 (1H, s), 7.37 (1H, s), 7.41 (1H, s), 7.74 (1H,
s), 8.32 (1H, s);

13

C NMR (CDCl3): δ 23.00, 29.94, 44.35, 56.10, 56.22, 58.57, 58.60,

104.44, 105.51, 107.64, 109.22, 126.72, 175.89. EIMS calcd for C23H23NO7 m/z
425.147; found 426.149.
Synthesis of (S)-3-hydroxy-2,6,7-trimethoxy-13,13adihydrodibenzo[f,h]pyrrolo[1,2-b]isoquinoline-11,14(9H,12H)-dione (34)
Compound 33 (0.5 g, 1.18 mmol) was dissolved in DCM (40 mL) and (CO) 2Cl2 (0.4 mL,
3.15 mmol) was added dropwise with DMF (1-2 drops). Mixture was stirring for 1.5 h at
room temperature. Then, it was brought to 35 °C, to add SnCl 4 (0.6 mL, 2.30 mmol) for
4 h under N2 atmosphere. The reaction was cooled to room temperature and was added
cold 2 N HCl (3.5 mL). The solution was extracted withCHCl3 and H2O. The organic
phase was separated and dried with Na2SO4, filtered, and solvent removed by rotary
evaporation. Crude product was purified by column chromatography (2:1:0.3
CHCl3:EtOAc:MeOH) to give 34 0.35 g. (60-75 % yield) mp: 220 °C (lit.6 220 °C).
1

HNMR (CDCl3): δ 2.14 (2H, m), 2.39 (2H, m), 4.01 (3H, s), 4.05 (3H, s), 4.12 (3H, s),

4.37 (1H, d), 4.67 (1H, d), 5.72 (1H, d), 7.23 (1H, s), 7.72 (1H, s), 8.09 (1H, s), 9.16 (1H,
s);

13

C NMR (CDCl3): δ 20.68, 29.64, 40.71, 55.89, 56.27, 61.07, 103.44, 103.46,

104.39, 120.98, 195.13, 173.71. EIMS calcd for C23H21NO6 m/z 407.137; found 408.137.
Synthesis of (13aS,14S)-3,14-dihydroxy-2,6,7-trimethoxy-12,13,13a,14tetrahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-11(9H)-one (35)
Compound 34 (3.81 g,9.36 mmol) was added THF (25 mL) under N2 gas at -10 °C.
Then K-selectride (1.0 M solution in tetrahydrofuran) (3.1 mL, 13.95 mmol) was added
and stirred for 5 h. The solution was added 2 N HCl (2 mL). Then, organic phase was
extracted with CHCl3 and water. The solvent was removed by rotary evaporation and
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purified by column chromatography. (2:1:0.3 CHCl3:EtOAc:MeOH) to give 35 (3.25 g, 75
% yield) mp 160 °C (lit.6 160 °C). 1HNMR (CDCl3): δ 2.09 (2H, m), 2.28 (2H, m), 2.86
(1H, m), 4.45 (1H, d), 5.15 (1H, d), 5.52 (1H, d), 7.17 (1H, s), 7.52 (1H, s), 7.81 (1H, s),
7.97 (1H, s);

13

C NMR (CDCl3): δ 21.72, 30.02, 45.51, 60.51, 67.55, 104.01, 104.71,

108.81, 108.92. EIMS calcd for C23H23NO6 m/z 409.153; found 410.155.
Synthesis of (13aS, 14S)-2,6,7-trimethoxy-9,11,12,13,13a,14hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinoline-3,14-diol (36)
To a mixture of LiAlH4 (0.2 g, 7.11 mmol) in THF (60 mL) at -10 °C was added dropwise
a solution of 35 (0.27 g, 0.66 mmol) in THF. Ice bath was removed and solution was
stirred at room temperature overnight. The solution was brought back to -10°C and
EtOAc (50 mL) was added dropwise, then Na2SO4·10H2O was added. The use of 2 N
HCl to quench the reaction proved to lower the yield. The solution was filtered and
solvent was removed by rotary evaporation. The crude product was purified by column
chromatography (2:1:0.5 CHCl3:EtOAc:MeOH) to give 11 0.15 g (60 % yield) mp 168 °C
(lit.6 170 °C). 1H NMR (CDCl3): δ 2.08 (2H, m), 2.24 (2H, m), 2.40 (1H, m), 2.47 (2H, m),
3.40 (1H, d), 3.94 (3H, s), 3.98 (3H, s), 3.99 (3H, s), 5.13 (1H, d), 7.19 (1H, s), 7.60 (1H,
s), 7.89 (1H, s), 8.04 (1H, s);

13

C NMR (CDCl3): δ 23.03, 23.04, 53.85, 55.57, 55.66,

55.70, 55.72, 65.80, 65.83, 103.70, 103.72, 103.86, 105.22. EIMS calcd for C 23H25NO5
m/z 395.173; found 396.173.
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Experimental procedure for DCB 3509
Synthesis of (13aS, 14S)-3-(3-hydroxypropoxy)-2,6,7-trimethoxy9,11,12,13,13a,14-hexahydrodibenzo[f,h]pyrroolo[1,2-b]isoquinolin-14-ol (37)
To a solution of 36 (30 mg, 75.92 μmol) in acetone (15 mL) was added 3bromopropanol (60 mg, 434.88 μmol) and K2CO3 (0.1 g). The solution was heated to 65
°C for 48 hours. At room temperature, the solution was filtered and washed with CHCl 3.
The solvent was removed by rotary evaporation and concentrated to obtain an oil. The
crude product was purified by column chromatography CHCl3:EtOAc:MeOH (2:1:0.5) to
give 37 (30-60 mg, >90 % yield) as powder. mp 265 °C. EIMS calculated for
C26H31NO6 m/z 453.215; found: 454.219

Experimental procedure for biotinylated tylophorine analog
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Synthesis of (13aS, 14S)-3-(6-bromohexyloxy)-14-hydroxy-2,6,7-trimethoxy12,13,13a,14-tetrahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-11(9H)-one (38)
To a solution of intermediate 35 (0.07 mg, 0.17 mmol) and acetone (100 mL) was added
1,6-dibromohexane (0.2 mL, 0.83 mmol) and K2CO3 (0.4 g). The solution was refluxed
to 70 °C for 48 hours. At room temperature, the solution was filtered and washed with
CHCl3. The solvent was removed by rotary evaporation and concentrated to obtain an
oil. The crude product was added EtOAc:hexanes:Et 2O (2:1:1) and left stirring for 30
minutes, then product precipitated to give 38 (70-100 mg, >90 % yield) as yellow
powder. mp 287 °C. 1H NMR (CDCl3): δ 1.3 (2H,m), 1.61 (2H,m),1.8 (2H,m), 1.98
(2H,m), 2.3 (1H,m), 2.32 (1H,m), 2.5 (1H,m), 2.52 (1H,m), 2.62 (1H.m), 3.5 (2H, m), 3.8
(3H, s), 3.91 (1H,m), 4.05 (3H,s), 4.08 (3H, s), 4.24 (2H, t), 4.43 (1H, s), 5.12 (1H,m),
5.22 (1H,s), 6.84 (1H,s), 7.63 (1H,m), 7.71 (1H, s), 7.78 (1H, s);

13

C NMR (CDCl3): δ

28.4, 29.04, 31.69, 32.6, 32.69, 34.01, 40.1, 41.15, 56.06,56.07,56.08, 61.2, 65.87,
69.35, 103.19, 103.37, 104.86, 105.19, 175.56. EIMS calculated for C24H29NO5 m/z
571.157, found: 572.167, 5.74.167.
Synthesis of 3-(6-azidohexyloxy)-14-hydroxy-2,6,7-trimethoxy-12,12,13a,14tetrahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-11(9H)-one (39)
To a solution of intermediate 38 (30 mg, 56.15 μmol) and DMF (3 mL) was added NaN 3
(0.1g). The solution was left refluxing to 80 °C overnight. The solvent was removed by
high vacuum evaporation. The crude product was purified by column chromatography
(2:1:0.5) CHCl3:EtOAc:MeOH to give 39 as an oil (30-70 mg, 70 - 90 %). mp 295 °C. 1H
NMR (CDCl3): δ 1.30 92H,m), 1.53 (1H,m), 1.61 (1H,m), 1.69 (1H,m), 1.79 (2H,m), 1.99
(1H,m), 2.29 (1H,m), 2.50 (1H,m), 2.59 (1H,m), 2.60 (1H,m) 2.72 (1H,m), 3.40 (2H,t),
3.83 (1H,m), 3.92 (3H,s), 4.06 (3H,s), 4.08 (3H,s), 4.23 (2H,t), 4.43 (1H,d), 5.16 (1H,s),
5.22 (1H,d), 6.88 (1H,s), 7.60 (1H,s), 7.69 (1H,s), 7.77 (1H,s);

13

C NMR (CDCl3): δ

19.41, 26.71, 26.72, 29.20, 31.03, 34.84, 41.15, 55.92, 56.20, 56.25, 58.57, 61.00,
65.70, 69.19, 103.03, 103.30, 104.53, 104.86, 175.50. EIMS calcd for C 29H34N4O6 m/z
534.25; found 535.25
Synthesis of (13aS,14S)-3-(6-aminohexyloxy)-2,6,7-trimethoxy-9,11,12,13,13a,14hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-14-ol (40)
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To a mixture of LiAlH4 (0.15g, 3.94 mmol) in THF (10 mL) at - 10°C was added
dropwise a solution of 39 (50 mg, 93.59 μmol) in THF. Ice bath was removed and
solution was stirred at room temperature overnight. The solution was brought back to –
10 °C and was added EtOAc (20 mL), H2O (10 mL), 3 M NaOH (7.5 mL), and H2O (10
mL) dropwise. The solution was filtered with celite and solvent was removed by vacuum
evaporation at room temperature. The crude product was used for the next step without
any purification. The amine test using ninhydrin turned positive: purple. EIMS calculated
for C29H38N2O5 m/z 494.28; found 495.29.
Synthesis

of

N-(6-((13aS,14S-14-hydroxy-2,6,7-trimethoxy-9,11,12,13,13a,14-

hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinolin-3-yloxy)hexyl)-5-((3aS,4aS,6aR)-2oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide (41)
A solution of biotin (0.01g, 0.04 mmol) in DMF (2 mL) under N2 gas was added HBTU
(0.01, 0.03 mmol), and DIPEA (0.05 mL). This solution was left stirring overnight at
room temperature. Then, intermediate 40 (0.01g, 0.02 mmol) in DMF (1 mL) was added
dropwise. The whole solution was left stirring at room temperature overnight. DMF was
evaporated under high vacuum pressure at room temperature, then the following
solvents were added: MeOH: Et2O (2:10) and left in the refrigerator overnight to form a
white precipitate. EIMS calculated for C39H52N4O7S m/z 720.36; found [M+Na]+ = 743.35
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Chapter Two: Synthesis of DCB 3507

2.2.1 Synthesis of (E)-2,3-bis(3,4-dimethoxyphenyl)acrylic acid (13)
2.2.1.1 Condensation reaction to give C
Experimental conditions and observations in detail:

Scheme 39: Condensation reaction to obtain C
First step: the solution was left stirring until it reached room temperature.
Second step: Water (150 mL) was added to decompose the unreacted Ac2O. The
temperature increased quickly, so the water had to be added slowly. It could get as high
as 60 °C.
Third step: An aqueous solution of K2CO3 (150g/500 mL) was added, which caused
foaming (CO2 evolution). This solid/liquid solution was reheated until reflux to ensure
completely dissolved; then, the solution was left stirring overnight at room temperature.
Potassium carbonate was added to eliminate water and form the alkene. Scheme
Fourth step: The organic phase was separated with ethyl ether. The aqueous layer
contained the cationic product. The organic layer was washed three times.
Fifth step: The aqueous solution was quenched with concentrated HCl. The acid was
added dropwise with stirring. At the beginning the solution had a pH 10. As the solution
became more acidic, it formed a sticky brown solid that stopped the stirring bar. In order
to avoid this problem, the addition of HCl had to be slowly. A yellow precipitate started
to form at pH 4.5–6. The addition of HCl continued until pH 1. The solution was left
stirring overnight to maximize the conversion to product C. This precipitate was
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separated and recrystallized with methanol at 65 °C. The final percent yield was
between 70–80% after recrystallization.
2.2.1.2 Condensation reaction to give (13)
Experimental conditions and observations in detail:

Scheme 40: Condensation reaction to obtain 13
The same first, second, third, fourth, and fifth steps we repeated to synthesize
13. The product 13 was consistently improved until a constant 95% yield. It was noticed
that during quenching the reaction with HCl at pH ~ 5-7, a large amount of precipitate
was formed which, seemed the right product; however, as the pH decrease to
approximately pH 4-5, a yellowish sticky solid, formed that was unmanageable. A first
attempt to avoid this problem to quenched at pH 5.5 and recrystallized the product. This
white crystalline product partially dissolved in CHCl3. It was determinated that this
product was a mixture of salts and did not give a satisfactory esterification reaction in
the next step.
A second attempt to overcome this problem was to add all reagents slowly. The
first, second, and third steps were gradually carried out. Normally, it took two hours to
complete the four steps, but in this case the addition of water and aqueous solution of
K2CO3 were added dropwise. It took five hours for the first three steps. For the fourth
step, the aqueous solution was quenched in an ice bath and HCl was added dropwise.
It took two hours to decrease the pH 1. At pH 1, the solution did not form any sticky
solid and precipitated a clean yellow product.
As final review about this Perkin reaction, the addition of water and aqueous
solution of K2CO3 must be added slowly. Then, the acidic quenching must be taken to
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pH 1 with diluted HCl solution (2 N HCl), which is added dropwise to avoid the formation
of any sticky solid.
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